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Facilitated by -omic data, precision medicine is a promising medical model that 
may revolutionize the quality of the current healthcare system. Currently, -omic data are 
being rapidly accumulated because of the advent of high-throughput -omic assays. 
Though challenging, abundant information embedded in these data is encouraging for the 
realization of precision medicine. Data analytics, including data pre-processing and data 
modeling techniques, has been successfully applied to many -omic applications, and 
biomarkers identified from -omic data are viewed as catalyzers for precision medicine. 
The goal of my Ph.D. research is to address some key challenges in the process 
from raw -omic data to disease subgroup assignment for precision medicine, including 
(1) the lack of standardized bioinformatics pipelines that extract high-quality gene 
expression from the raw RNA sequencing data; (2) the lack of systematic, quantitative 
assessment of the contribution of upstream bioinformatics pipeline components to 
downstream variations in identified biomarkers or clinical endpoint prediction 
performance; and (3) the lack of effective strategies for integrating knowledge derived 
from multiple -omic data sources, either the same type or different types. This 
dissertation addresses these challenges through three specific aims:  
(1) Quality Control for Precision Medicine:  to investigate and control the impact 
of bioinformatics pipelines on feature quality using RNA sequencing data. 
(2) Knowledge Discovery for Precision Medicine:  to discover impactful 
biomarkers that facilitate disease subgroup assignment using NGS data 
 xvii 
(3) Integrative Analysis for Precision Medicine:  to integrate multiple sources of 
-omic data for improved disease subgroup assignment. 
The research in this dissertation was completed in frequent collaboration with the 
Food and Drug Administration, Children’s Healthcare of Atlanta, Emory University, and 
Georgia Institute of Technology. Proposed analytical approaches for NGS data have been 
systematically evaluated and validated using a variety of experimental designs with 
various NGS datasets. These results and associated case studies demonstrate the 
contribution of this work to and its future potential in the paradigm shift from current 





CHAPTER 1    
INTRODUCTION 
 
Providing the best health care for patients is always the driving force for the 
transformation of the healthcare system. Many medical models have been proposed for 
improving the healthcare system, and personalized medicine was the most attractive, 
promising model, aiming to customize healthcare delivery for each individual and to 
maximize the effectiveness of each patient’s treatment [1]. The concept of personalized 
medicine has had a long history, but its development really speeded up only after the 
completion of the Human Genome Project, leading to the rapid advancement of 
functional genomics that in turn enables more precise risk estimation and therapeutic 
response prediction [2]. A further improvement of the current healthcare system was 
advocated by Hood et al. since 2009. They proposed the concept of predictive, 
personalized, preventive, and participatory medicine (P4 medicine), which aims to 
transform current reactive medicine to future proactive medicine [3]. Such a major 
paradigm shift may potentially reduce healthcare expenditure and ameliorate patients’ 
prognosis. Recently, momentum has been accumulated for moving from personalized 
medicine to precision medicine. The subtle but fundamental difference between 
personalized medicine and precision medicine is that precision medicine pursues a more 
precise classification of patients into subgroups that share a common biological basis of 
diseases [4, 5]. Such a precise classification may potentially lead to more effective 
treatments and better clinical outcomes, and this is exactly the promise of precision 
medicine advocated by President Barack Obama in his State of the Union Address in 
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January 2015:  “… delivering the right treatments, at the right time, every time to the 
right person …” [6].  
Precision medicine presents a promising paradigm shift from early symptom-
based intuition medicine, today’s patterned-based, evidence-based medicine, to future 
algorithm-based medicine (Figure 1). The key to precision medicine centers around the 
data, including data collection, data management (e.g., data storage, data sharing, and 
data privacy), and data analytics (e.g., data mining, data integration, data interpretation, 
and data visualization) [7]. All these data-related components were also brought up in a 
statement from The White House:  “… the Precision Medicine Initiative will leverage 
advances in genomics, emerging methods for managing and analyzing large data sets …” 
[8]. As technologies evolved, a tremendous amount of biomedical data has been 
generated and stored. These biomedical data are viewed as big data because of their high 
complexity and typically large volume [9]. Currently, biomedical big data and associated 
big data analytics have been applied to several key research areas, including, but not 
limited to, bioinformatics [10-12], health informatics [13-16], biomedical imaging 
informatics [17-19], and biosensor informatics [20-22]. It was only recently that -omic 
data were identified as the main catalyzer for precision medicine, and integrating -omic 
data into the current electronic health record (EHR) system is one most probable 




Figure 1:  Evolution of Healthcare Models. Models for health care are ever-changing, 
and their ultimate goals are to provide the most effective treatment for every patient. 
With tons of stored biomedical big data and the advancement in algorithms and analytics, 
it is promising to move from today’s pattern-based, evidence-based medicine to future 




The fast accumulation of -omic data largely owes to the invention of several high-
throughput technologies such as next-generation sequencing (NGS), microarrays, and 
high-resolution mass spectrometry (Figure 2). These high-throughput technologies 
facilitate the collection of various types of -omic data, including genomic, transcriptomic, 
epigenomic, proteomic, and metabolomic (Figure 2). Each type of -omic data possesses 
its unique aspects of personalized information about a patient. Thus, by integrating 
knowledge derived from various types of -omic data, it is possible to identify a set of 
rules or characteristics that may help precisely categorize patients into disease subgroups, 
which is the essence of precision medicine. The concept of precision medicine is 
promising, and the data that support this concept has been constantly generated. 
However, the connection between the concept and the raw -omic data is still in its 
infancy. With such overwhelming data complexity and volume, it is necessary to have 
novel analytics for handling and analyzing these big data (Figure 2) [25]. Following the 
DIKW (data, information, knowledge, and wisdom) hierarchy [26], -omic data analytics 
mainly focuses on extracting molecular profiles from raw data generated by high-
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throughput assays, deriving biological knowledge from raw molecular information, 
integrating knowledge derived from various types of -omic data, and finally concluding 





Figure 2:  Personal Molecular Fingerprints. Each individual has unique molecular 
fingerprints that are mainly composed of DNA, RNA, protein, and metabolite profiles. 
Next-generation sequencing and mass spectrometry are two popular high-throughput 
assays that help extracting raw -omic data, including genomic (DNA), transcriptomic 
(RNA), epigenomic (DNA), proteomic (proteins), and metabolomic (metabolites). With 
proper data analytics, it is possible to identify actionable knowledge for precision 







Figure 3:  DIKW Hierarchy for -Omic Data. DIKW stands for data, information, 
knowledge, and wisdom. Following the DIKW hierarchy, data analytics for -omic data 
plays the role of extracting personal molecular fingerprints (Data to Information), 
discovering all available -omic knowledge (Information to Knowledge), integrating 
knowledge from multiple -omic data (Knowledge to Wisdom), and finally identifying 




Among high-throughput -omic assays, the most popular one for acquiring 
genomic, transcriptomic, and epigenomic data is the NGS technology. Therefore, the 
majority of my thesis work centered on developing data analysis pipelines for NGS data, 
with a focus on RNA sequencing, which is one of the most important applications of the 
NGS technology. The rest of this introduction aims to provide some background 
information about my thesis work, beginning with the NGS technology, followed by 
various types of -omic data (i.e., genomic, transcriptomic, and epigenomic) generated by 
NGS and associated -omic features. I then introduce the current state of the art in feature 
extraction and biomarker identification for NGS-based -omic data, followed by the 
detailed elaboration of RNA sequencing expression analysis pipelines. Finally, I end with 
a discussion of bioinformatics challenges in the DIKW hierarchy for NGS data that 
motivate my thesis work formulated in three specific aims. 
1.1   Next-Generation Sequencing Technologies 
Commercially available and widely applied NGS platforms include Illumina, Ion 
Torrent, and Roche/454. These platforms differ primarily in the experimental basis and 
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protocol but share similar sequencing steps. In general, after sequencing library 
preparation, DNA/cDNA fragments are isolated and attached to a substrate. These 
fragments are amplified and then sequenced in parallel. The iterative sequencing steps, 
followed by fluorescence imaging, produce a large set of imaging data that will be 
translated into sequence “reads” by platform-specific base-calling algorithms. 
Illumina is the most prevalent NGS platform that uses a “sequencing-by-
synthesis” technique. DNA/cDNA molecules are fragmented, ligated with adapters, 
attached to a proprietary flow cell surface, followed by a bridge amplification process 
that forms clonally distributed clusters for each attached DNA/cDNA fragments. Using a 
cyclic reversible termination technique, four fluorescently-labeled nucleotides are fed to 
the flow cell with one and only nucleotide binds to each surface-bound fragment. These 
fluorescent dyes are then imaged and washed away before the next sequencing cycle [27]. 
Ion Torrent leveraged Moore’s Law in manufacturing semiconductors and invented a 
semiconductor chip that is capable of directly translating chemical signals into digital 
information. Similar to Illumina, adapter-ligated DNA/cDNA fragments are attached to 
the proprietary Ion Sphere particles, followed by emulsion PCR before depositing into 
wells on a semiconductor chip where the sensing process occurs [28]. Roche/454 
pyrosequencing is the earliest commercialized NGS platform also based on emulsion 
PCR for amplification. It determines nucleotide sequences by detecting the release of 
pyrophosphates when nucleotides are cyclically added [29]. 
1.2   NGS-based -Omic Data 
-Omic data contain a comprehensive catalog of molecular profiles in biological 
samples. They have been viewed as the fundamental driving force for precision medicine. 
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Major types of -omic data include genomic, transcriptomic, epigenomic, proteomic, and 
metabolomic, and NGS is the most popular assay for generating genomic, transcriptomic, 
and epigenomic data. 
The uniqueness property of each person’s genome as well as the closely related 
transcriptome and epigenome provides a promising opportunity for precision medicine. 
The advent of several high-throughput technologies, such as NGS and DNA microarrays, 
has offered the capability of studying the entire genome, transcriptome, and epigenome in 
a faster and more cost-effective manner. A genome contains a complete set of DNAs in a 
cell. Knowledge embedded in the genome includes single nucleotide polymorphisms 
(SNPs), insertions, deletions (indels), copy number variations (CNVs), and several other 
structural variations (SVs) [30, 31]. A transcriptome contains all kinds of RNAs (e.g., 
mRNA, tRNA, and rRNA) transcribed from the genome. Knowledge embedded in the 
transcriptome includes gene expression, transcript expression, gene fusion, and 
alternative splicing [32, 33]. Lastly, an epigenome contains genome-wide chemical 
modification or marking of DNA sequences. Such modification does not change DNA 
sequences but does influence downstream transcriptional mechanisms. Knowledge 
embedded in the epigenome includes genome-wide protein-DNA binding sites, histone 
modification patterns, and DNA methylation patterns [34]. Epigenomic data may be the 
most essential building block for pursuing precision medicine due to its role in affecting 
other -omic data, such as transcriptomic, proteomic, and metabolomic [35]. 
1.3   Feature Extraction Techniques for NGS-based -Omic Data 
Raw data generated by NGS are short sequence reads, or reads for short, that 
contain the reading of nucleotide sequences, either DNA or cDNA. These raw NGS-
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based -omic data are not directly interpretable, and the required feature extraction steps 
depend on the type of -omic data. Several selected tools for -omic data feature extraction 
are summarized in Table 1. 
NGS is a popular assay for genomic, transcriptomic, and epigenomic studies. 
Sequence mapping, which identifies not only the origin but also the alignment of each 
read, is the first step for most NGS applications [36]. It is a computationally intensive 
process that requires auxiliary data structures (e.g., the hash table [37] and the Burrows-
Wheeler transform [38]), multithreading, or in-memory computing [39] for improving 
computational efficiency. 
Genomic studies typically aim to identify genomic variants, either small-scale 
(e.g., SNPs) or large-scale (e.g., SVs), in the sequenced genome [40]. Small-scale variant 
detection uses per base differences between reads and the reference genome as the 
evidence [30, 41]. Large-scale variant detection applies various approaches, including 
read-pair-based, read-depth-based, split-read-based, and assembly-based [42, 43]. 
For transcriptomic studies, major applications include expression profiling, fusion 
gene detection, and alternative splicing detection [32, 33]. Expression profiling is a 
process that associates mapped reads with genes and corresponding transcripts. The main 
difference among various quantification methods is the handling of multi-mapped reads. 
Some methods associate the reads with all loci [44, 45], whereas others probabilistically 
associate the reads with only a few model-inferred loci [46, 47]. Gene fusion is a rare 
event that two partial genes combine and form a new gene. Fusion gene detection relies 
on two main evidence:  the spanning read pairs, which indicate that a fusion boundary 
exists between the two ends, and the split read, which provides more definite evidence for 
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the location of a fusion boundary [48, 49]. Alternative splicing is a process that includes 
or excludes certain exons when forming mature mRNAs. Detecting alternative splicing 
relies on either de novo transcriptome assembly [50-54], or inference from sequence-
mapping outputs [47, 55]. 
 
 
Table 1:  Selected Tools for -Omic Feature Extraction. 








Sequence mapping BWA [38] 
STAR [39] 
GATK [30] 




Gene expression quantification 
BEDTools [45] 
RSEM [46] Gene and transcript expression 
quantification Cufflinks [47] 
defuse [48] 
Gene fusion detection 
TopHat-Fusion [49] 
Trans-ABySS [50] 






Epigenomic ChIP-seq peak calling 
SISSRs [57] 
GMAP stands for genomic mapping and alignment program; BWA, Burrows-Wheeler aligner; STAR, 
spliced transcripts alignment to a reference; GATK, genome analysis toolkit; RSEM, RNA-seq by 
expectation-maximization; Trans-ABySS, transcriptome assembly and analysis pipeline; MACS, model-





Epigenomic studies focus on identifying putative DNA-binding sites, histone 
modification patterns, and DNA methylation patterns [34]. Since sample preparation 
protocols ensure only relevant genomic regions are sequenced, the feature extraction of 
epigenomic data usually contains the following three steps:  building a single profile 
representing the density of reads along the genome, modeling background noises, and 
finally determining statistically significant peaks [36]. 
1.4   Biomarker Identification Techniques for NGS-based -Omic Data 
Feature extraction techniques help derive interpretable -omic features from the 
raw -omic data. In practice, multiple groups of samples are collected, representing 
different biological conditions (e.g., disease verus non-disease) or different time points 
(e.g., before versus after a treatment). With such an experimental design, it becomes 
feasible to identify -omic biomarkers that are discriminatory among groups. Several 
selected tools for biomarker identification are summarized in Table 2. 
For genomics, not all variants have significant impact on phenotypic traits. The 
advent of genome-wide association studies (GWASs) helps assess the degree of 
association between each variant and a targeted trait [58]. However, GWAS presents 
some big limitations especially when dealing with complex diseases such as cancer and 
cardiovascular diseases [59]. Most GWAS tools focus on SNP association [60-62], while 
only a few can infer CNV or SV association [63, 64]. Most other -omic biomarkers are 
identified by investigating statistically significant differences among groups, such as 
differentially expressed genes/transcripts [65, 66], differential alternative splicing [67, 
68], differential DNA binding [69], differential histone modification [70], and differential 
methylation [71]. In general, the abundance of each group is quantified and fitted to 
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Poisson-based distributions (e.g., the Poisson distribution and the negative binomial 
distribution), followed by statistical tests (e.g., the Fisher’s exact test and the likelihood 
ratio test) that determine the statistical significance of each molecular feature. 
 
Table 2:  Selected Tools for -Omic Biomarker Identification. 
 
Tool -Omic Data -Omic Biomarker Approach 
SNPassoc [60] 
Genomic 







Significant SNPs and indels associated 
with traits 
PLINK [63] 
Significant SNPs, indels, and CNVs 
associated with traits 
CNVRuler [64] Significant CNVs associated with traits 
edgeR [65] 
Transcriptomic 













Differential binding sites 
ChIPDiff [70] Differential histone modification sites 
QDMR [71] Differentially methylated regions 
SNPassoc stands for SNP-based whole genome association studies; VAT, variant association tools; PLINK, 
population-based linkage analyses; edgeR, empirical analysis of digital gene expression data in R; MATS, 
multivariate analysis of transcript splicing; DBChIP, differential binding with ChIP-seq data; and QDMR, 




1.5   RNA Sequencing Expression Analysis Pipelines 
RNA sequencing, or RNA-seq for short, is a major branch of NGS. It is capable 
of capturing comprehensive transcriptomic information such as gene expression, 
transcript expression, gene fusion, and alternative splicing [32]. To capture the highly 
dynamic transcriptome, one popular application of RNA-seq is to study gene and 
transcript expression among various biological conditions or samples collected at various 
 12 
time points [33]. In the first step of RNA-seq expression analysis pipeline, sequence 
reads are mapped to a reference genome or transcriptome. Next, the quantification step 
estimates gene or transcript expression. Finally, the normalization step enables inter- or 
intra-sample comparison. RNA-seq-based inferences typically based on modeling the 
normalized gene or transcript expression [72] that will be discussed in later chapters. 
1.5.1   Sequence Mapping 
The first step of bioinformatics pipelines for most NGS-based applications is 
sequence mapping, and the RNA-seq expression analysis pipeline falls within this 
category. Sequence mapping determines the genomic or transcriptomic origin of 
sequence reads (or “reads” for short). The brute-force strategy for sequence mapping 
requires large CPU and memory resources. For example, mapping millions of reads to the 
three billion base pairs (bp) of the human genome is extremely time-consuming. Thus, 
the research of sequencing mapping largely focuses on improving computational 
efficiency while maintaining high mapping accuracy.  
Table 3 lists some mapping tools with their mapping strategies and key features. 
Depending on biological applications and computational resources, mapping algorithms 
can provide three types of alignments:  (1) Un-gapped alignment (e.g., Bowtie [73]) 
allows only mismatches between query reads and the reference genome to keep the 
computational cost low. However, for some applications (e.g., mapping of RNA-seq data 
to the human genome), un-gapped alignment may fail to align a large number of reads. 
(2) Gapped alignment (e.g., BFAST [74], Bowtie2 [75], BWA [38], Novoalign [76], 
SHRiMP2 [77], SOAPaligner [78], and SSAHA2 [79]) allows mismatches, insertions, 
and deletions. Most gapped alignment tools implement the Smith-Waterman [80] or 
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Needleman-Wunsch [81] algorithms. (3) Spliced alignment (e.g., GSNAP [82], TopHat 
[83], MapSplice [84], OSA [85], and SOAPsplice [86]) allows the long extension of gaps 
within the query reads. Biologically, such long gaps may represent intronic regions or 
inter-chromosomal splitting. Algorithmically, spliced alignment may be achieved by 
segmenting query reads into smaller sequences (e.g., 25 bp), mapping these smaller 
sequences, and then assembling mapped results for each read into a consensus result. 
Spliced alignment algorithms are often computationally more expensive than un-spliced 
algorithms. However, spliced mapping is necessary for applications that focus on 
identifying novel splice junctions using RNA-seq. Un-spliced mapping, including gapped 
and un-gapped, is sufficient for ChIP-seq data analysis. 
Mapping accuracy depends on mapping strategy. Uniquely mapped reads provide 
more definite information than multi-mapped reads. If a query read is mapped to multiple 
genomic loci due to short read length, the ambiguous mapping happens and a mapping 
tool may randomly report one mapping out of all optimal mappings or report all optimal 
mappings. On the other hand, multi-mapped reads may benefit the downstream 
quantification algorithms in model training and expression estimation.  
To improve the computational efficiency of sequence mapping, auxiliary data 
structures can be used to reduce the similarity search space such as to index either the 
reference genome or query reads using hash tables (e.g., BFAST, GSNAP, SHRiMP2, 
and SSAHA2 are representatives), or to index the reference genome using the Burrows-
Wheeler transform with suffix/prefix arrays (e.g., Bowtie, Bowtie2, BWA, and SOAP2 
















to transcriptome or 
genome 
Hash table, Smith-Waterman local alignment 
Bowtie [73] Burrows-Wheeler transform and FM-index 
Bowtie2 [75] 
Burrows-Wheeler transform, FM-index-assisted 
seed alignment, dynamic programming 
BWA [38] Burrows-Wheeler transform 
Novoalign [76] *Commercial software, algorithm un-published 
SHRiMP2 [77] 
Multiple spaced-seed indexing, Smith-Waterman 
local alignment 
SOAPaligner [78] Bi-directional Burrows-Wheeler transform 
SSAHA2 [79] Hash table 
GSNAP [82] 
Spliced mapping to 




Minimal sampling strategy, oligomer chaining for 
approximate alignment, sandwich dynamic 
programming 
MapSplice [84] 
Spliced mapping to 
genome 
Uses Bowtie for alignment, segmented mapping  
OSA [85] 
Two-stage transcriptome and genome alignment, 
segmented mapping 
SOAPsplice [86] Burrows-Wheeler transform, segmented mapping 
TopHat [83] 
Uses Bowtie or Bowtie2 for alignment, 
segmented mapping 
BFAST stands for BLAT-like fast accurate search tool; BWA, Burrows-Wheeler aligner; SHRiMP2, short 
read mapping package, version 2; SOAPaligner, short oligonucleotide analysis package aligner; SSAHA2, 
sequence search and alignment by hashing algorithm, version 2; GSNAP, genomic short-read nucleotide 
alignment program; OSA, Omicsoft sequence aligner; and SOAPsplice, short oligonucleotide analysis 






1.5.2   Expression Quantification 
The second step of the RNA-seq bioinformatics pipeline is expression 
quantification of genes or transcripts. Because a read may map to multiple genomic loci, 
the accuracy of gene or transcript expression estimation depends on the ability of a 
quantification algorithm to resolve the ambiguities from the sequence-mapping step. In 
addition, a gene may have multiple alternatively spliced transcripts sharing a common set 
of exons, where a read mapped to the shared exons may belong to any one of the 
transcripts. Currently, the handling of these ambiguities involves building a probabilistic 
framework and then estimating gene or transcript expression using either the expectation-
maximization (EM) algorithm or Bayesian inference [46, 47, 88]. 
Quantification algorithms can be categorized into three groups:  count-based, 
linear model-based, and Poisson model-based [89]. Table 4 lists common RNA-seq 
quantification tools, categorized in terms of the model, the estimation algorithm, and 
quantifiable targets. Count-based quantifiers (e.g., ERANGE [90], HTSeq [44], NEUMA 
[91], and ALEXA-Seq [92]) assign each read to its mapped location with a probability of 
one. Each count-based quantifier implements a proprietary filtering criterion, and the 
expression profile is the accumulated read count on each targeted gene or transcript. 
Linear model-based quantifiers (e.g., rQuant [93] and IsoInfer [94]) assume that read 
counts are normally distributed, and least squares can be applied to infer expression 
estimates. Poisson model-based quantifiers (e.g., RSEM [46], Cufflinks [47], MISO [88], 
and IsoEM [95]) probabilistically assign multi-mapped reads based on the assumption 
that reads from genomic loci follow the Poisson distribution. Count-based quantifiers do 
not rely on a predefined model, so they have lower computational complexity than 
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model-based quantifiers. However, the expression estimates of count-based quantifiers 
















Average coverage of mapped reads Yes / Yes 
ERANGE [90] 
Accumulated counts, read assigns 
proportionally to expression level 
Yes / No 
HTSeq [44] 
Accumulated counts, read assigns with 
probability 1 
Yes / No 
NEUMA [91] Accumulated counts of informative reads Yes / Yes 
IsoInfer [94] 
Linear model 
Maximum likelihood estimation from 
convex quadratic programming 
Yes / Yes 
rQuant [93] 
Minimize read coverage deviation with 
quadratic programming 
Yes / Yes 
Cufflinks [47] 
Poisson model 
Maximize likelihood with the maximum a 
posteriori estimates using Bayesian 
inference 
Yes / Yes 
IsoEM [95] 
Maximum likelihood estimation with EM 
algorithm 
Yes / Yes 
MISO [88] 
Posterior mean estimates using Bayesian 
inference 
Yes / Yes 
RSEM [46] 
Maximum likelihood estimation with EM 
algorithm 
Yes / Yes 
ALEXA-Seq stands for alternative expression analysis by sequencing; ERANGE, enhanced read analysis 
of gene expression; HTSeq, analyzing high-throughput sequencing data with Python; NEUMA, 
normalization by expected uniquely mappable area; IsoInfer, inference of transcripts from short sequence 
reads; rQuant, transcript quantification with RNA-seq data; IsoEM, transcript quantification by expectation 






1.5.3   Expression Normalization 
The third step of the RNA-seq bioinformatics pipeline is expression 
normalization. Because of variations introduced in sequencing and bioinformatics 
processes, inter- or intra-sample comparisons of RNA-seq expression estimates can only 
be done after normalization. Most normalization methods for RNA-seq are based on 
scaling, in which the gene or transcript expression of any biological sample is normalized 
by multiplying or dividing by a fixed scaling factor. Therefore, the fundamental challenge 
for RNA-seq expression normalization is to estimate a set of robust scaling factors for 
samples in the dataset. Table 5 lists commonly used RNA-seq normalization methods. 
Several naïve methods such as RPM / FPM (reads / fragments per million mapped 
reads / fragments), median normalization, and upper-quartile normalization [96] are 
mathematically similar. RPM / FPM adjust expression estimates of each sample by the 
total number of mapped reads/fragments in the sample. Median and upper-quartile 
normalizations use the median and upper quartile read / fragment counts, respectively, of 
each sample as the substitute for the total mapped reads / fragments. With the Illumina 
sequencing protocol, longer genes or transcripts tend to produce a larger number of 
sequence fragments. Thus, some methods such as RPKM / FPKM (reads / fragments per 
kilobase per million mapped reads / fragments) [90] and TPM (transcripts per million) 
[46] further adjust expression estimates by gene or transcript length, which in turn 
enables both inter- and intra-sample comparisons. However, there exist limitations for the 
aforementioned normalization methods. For the RPKM / FPKM, gene or transcript length 
cannot be precisely defined. Also some methods such as RPM / FPM and RPKM / FPKM 
are sensitive to “extreme” datasets that have a small number of highly differentially 
 18 
expressed genes. Therefore, a number of methods such as TMM (trimmed mean of M-
values) [97] and RLE (relative log expression) [98] assume that most genes are not 
differentially expressed and use a robust estimate of library sizes as the scaling factors. 
Dillies et al. systematically evaluated a few normalization methods and recommended 
TMM or RLE as the most robust method for most RNA-seq data [99]. 
 
Table 5:  Summary of Expression Normalization Methods for RNA-seq. 
 
Normalization Method Description 
Median Scaling by median of all counts 
Quantile Matching distributions of counts 
RLE Scaling by median ratio to median library 
RPKM/FPKM Scaling by library size and gene/transcript length 
RPM/FPM Scaling by library size 
TMM Scaling by estimate of relative RNA production 
TPM Scaling by mean length of expressed genes/transcripts 
Upper Quartile Scaling by upper quartile of all counts 
RLE stands for relative log expression; RPKM/FPKM, reads/fragments per kilobase per million mapped 
reads/fragments; RPM/FPM, reads/fragments per million mapped reads/fragments; TMM, trimmed mean 




1.6   Bioinformatics Challenges in the DIKW Hierarchy for NGS Data 
The DIKW hierarchy is a framework that depicts the process from data to 
information, knowledge, and final wisdom (Figure 3). In the context of my thesis work, 
data refers to raw -omic data generated by NGS, information refers to extracted -omic 
features, knowledge refers to biomarkers or any patterns hidden in the -omic features, and 
wisdom refers to actionable knowledge for precision medicine. Linking components in 
this hierarchy requires various data analytics, and it is very challenging due to many 
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inherent properties in the -omic data such as data collection frequency, data quality, data 
dimensionality, data heterogeneity, and analytical pipeline complexity. These challenges 
motivate the specific aims of my thesis work, and more details of these challenges are 
discussed as follows: 
Diverse Data Collection Frequency 
For different -omic data modalities, data collection frequency varies 
tremendously. For example, a genome is invariant over a long period of time and often 
needs only one-time data acquisition, while other types of -omic data (e.g., transcriptomic 
and epigenomic) vary with environment, tissue types, and time that would require multi-
time-point, multi-sample-source acquisition. 
Inherent Data Quality Issues 
In -omic data, quality issues are caused by a combination of biological, 
instrumental, and environmental factors such as sample contamination [100, 101], batch 
effects [102, 103], and low signal-to-noise ratios [104, 105]. These data quality issues 
may lead to wrong conclusion, but correcting these remains challenging. 
High Dimensionality 
An inherent challenge in data mining applications using -omic data is high data 
dimensionality. -Omic data often feature many dimensions or features (may be more than 
10
4
) much larger than the number of samples available [106-108]. This results in the 
“curse of dimensionality,” a term which describes the phenomenon where the increasing 
dimensionality of the data exponentially increases the volume of the space needed to 
describe it, leading to increasingly sparse data filling the space [109]. 
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Heterogeneous Data Type 
In -omics, using underlying molecular fingerprints to characterize disease 
subtypes may require heterogeneous multi-omic data. For example, the integrative 
personal omics profile (iPOP) project has integrated multiple molecular expression 
profiles to uncover dynamic molecular changes between healthy and diseased states 
[110]. However, integrating multi-omic data is challenging because of variations in 
represented biological processes, technical and biological noise levels, identification 
accuracy, spatiotemporal resolution, and many other confounding factors [111]. 
High Analytical Pipeline Complexity 
Ever since NGS became the most popular high-throughput assay for genomics, 
transcriptomics, and epigenomics, many bioinformatics solutions have been propose to 
extract -omic features from raw -omic data. Feature extraction for -omic data is a multi-
step process and each step may have more than dozens of solutions. The high analytical 
complexity comes from all possible combinations of pipeline components for each NGS-
based application. It has been known that significant variations in extracted -omic 
features exist that may be induced by data acquisition or pipeline variability. However, 
until now, no clear consensus about the choice of bioinformatics pipelines and its impact 
on downstream analysis has been established [36, 112, 113]. 
1.7   Structure of Dissertation 
Motivated by the existing challenges mentioned in the previous section, I have 
formulated the overall objective and three specific aims of my thesis work as follows:  
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Overall Objective:  To investigate and develop integrative bioinformatics approaches for 
extracting and discovering robust molecular knowledge for realizing future precision 
medicine.  
Specific Aim #1 (Quality Control for Precision Medicine):  To investigate and control 
the impact of bioinformatics pipelines on feature quality using RNA sequencing data. 
Specific Aim #2 (Knowledge Discovery for Precision Medicine):  To discover 
impactful biomarkers that facilitate disease subgroup assignment using NGS data. 
Specific Aim #3 (Integrative Analysis for Precision Medicine):  To integrate multiple 
sources of -omic data for improved disease subgroup assignment. 
With the aim to promote the Precision Medicine Initiative, Figure 4 summarizes 
the key areas where this dissertation improves the workflow from raw -omic data to 
disease subgroup assignment. The ultimate goal of precision medicine is to precisely 
classify patients into subgroups that share a common biological basis of diseases. The 
success of precision medicine relies on many building blocks, and my thesis work 
specifically addresses challenges from quality control, knowledge discovery, and 
integrative analysis perspectives. The quality control block ensures accurate -omic 
features being extracted from raw -omic data before discovering important knowledge for 
precision medicine (Specific Aim #1). The knowledge discovery block uses various 
models to identify key knowledge (e.g., distinguishing biomarkers) that facilitates precise 
disease subgroup assignment (Specific Aim #2). Finally, the integrative analysis block 
incorporates complimentary information from multiple sources that may lead to more 
precise disease subgroup assignment (Specific Aim #3). 
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Figure 4:  Overview of the Scope of This Dissertation. My thesis work aims to 
promote precision medicine by improving the workflow from raw -omic data generated 
by NGS to disease subgroup assignment. Many building blocks involve in this process, 
and my thesis work specifically focusses on quality control, knowledge discovery, and 




Chapter 2, Quality Control for Precision Medicine, addresses Specific Aim #1 by 
describing the experiment and evaluation-metric design that aims to establish RNA-seq 
expression analysis guidelines for accurate gene expression estimation. Two levels of 
investigation were conducted—pipeline component investigation and full pipeline 
investigation, and corresponding recommendations were provided. Chapter 3, Knowledge 
Discovery for Precision Medicine, addresses Specific Aim #2 by using statistical models 
and machine learning techniques to identify biomarkers that help classify patients into 
disease subgroups. Chapter 4, Integrative Analysis for Precision Medicine, addresses 
Specific Aim #3 by leveraging knowledge from multiple sources so as to improve the 
robustness of derived knowledge. Finally, Chapter 5, conclusion, provides concluding 
remarks, and highlights concrete deliverables that arose as a result of this dissertation. An 
outlook on future work for the Precision Medicine Initiative is also presented. 
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CHAPTER 2    
QUALITY CONTROL FOR PRECISION MEDICINE 
 
2.1   Introduction 
The first objective of this dissertation was to investigate and control the impact of 
bioinformatics pipelines on feature quality using RNA-seq data. As introduced in Section 
1.5, RNA-seq is a major branch of NGS that greatly facilitates transcriptomic research. 
Figure 5 shows the schematic diagram from biological samples of interests to raw RNA-
seq data generated by the NGS instrument. Among many RNA-seq applications, gene, 
transcript, or small RNA (e.g., miRNA) expression profiling and its downstream 
inferences have drawn much attention to researchers and clinicians and have brought 
huge impact to biology and medicine. As demonstrated in Figure 6, a typical RNA-seq 
expression analysis pipeline consists of sequence mapping, expression quantification, 
expression normalization, and one knowledge discovery step such as predictive modeling 
and differentially expressed gene detection. The first three components in the pipeline 
(i.e., sequence mapping, expression quantification, and expression normalization) are the 
focus of this chapter, and they are essential for extracting features (i.e., gene or transcript 
expression) from raw RNA-seq data. One key challenge of such the feature extraction 
process is that too many bioinformatics solutions are publicly available for each of the 
three components, and no consensus has been established about the impact of different 
choices of bioinformatics pipelines or pipeline components on downstream analysis and 
inferences. To ultimately promote precision medicine, it is important to control feature 
quality by investigating the performance of bioinformatics solutions for each pipeline 
 24 
component or the pipeline as a whole. This is the central theme of this chapter and will be 





Figure 5:  RNA Sequencing Workflow. The RNA sequencing, or RNA-seq for short, 
workflow starts from collecting samples of interests, followed by extracting RNA 
molecules in the samples, synthesizing cDNA molecules using reverse transcription 
techniques, preparing sequencing libraries, and finally running the NGS instrument to 
acquire raw RNA-seq data. The raw RNA-seq data are readings of RNA molecules in the 
samples. Currently, the most popular RNA-seq technique is called paired-end 












Figure 6:  RNA-seq Expression Analysis Pipeline. The typical RNA-seq expression 
analysis pipeline includes sequencing mapping, which maps raw RNA-seq data, or reads, 
to the reference genome or transcriptome; expression quantification, which quantifies 
expression levels of each genes or transcripts; expression normalization, which 
normalized gene or transcript expression so that they become comparable with one 
another; and finally knowledge discovery, which identifies predictive, statistically 








The rest of this chapter starts with the elaboration of feature extraction pipelines 
for RNA-seq data, followed by the introduction of evaluation metrics for pipeline 
performance assessment. I then use four case studies to showcase the investigation and 
control of the feature quality (i.e., the quality of gene or transcript expression) for 
precision medicine. The background, experimental design, datasets, and results of each 
case study are discussed based on their original publications [114-118]. A summary is 
provided at the end of this chapter with key accomplishments and innovations. 
2.2   Feature Extraction Pipelines for RNA Sequencing Data 
The thorough review of each pipeline component for RNA-seq expression 
analysis has been provided in Section 1.5. In this section, I mainly focus on introducing 
selected algorithms or methods I investigated in the four case studies as well as some 
complementary background to each component that has not been covered in Section 1.5. 
2.2.1   Sequence Mapping 
Inputs for Sequence Mapping Algorithms 
Sequence mapping algorithms usually take three input files—sequence reads 
generated by the NGS instrument, reference sequences (e.g., a reference genome or 
transcriptome), and a genome annotation. The objective is to map sequence reads to 
reference sequences with the guidance of the genome annotation if desired.  
The most well-known reference genome is UCSC (UC Santa Cruz) hg19, which 
mainly contains 24 primary chromosome contigs (i.e., chromosomes 1 to 22, X, and Y), 
20 unplaced contigs (sequences with known chromosome but unknown chromosomal 
location), and 39 unlocalized contigs (sequences with unknown chromosome). Most of 
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my studies used UCSC hg19 as the reference genome. The reference transcriptome is 
typically extracted from the reference genome using genome annotation information. 
Several organizations or institutions have spent more than a decade working on 
annotating the human genome. Various annotating techniques have been developed and a 
variety of information sources have been utilized to provide the most informative and 
correct human genome annotation [119, 120]. In Case Study 1, my investigation included 
six well-known annotations, such as AceView Genes, Ensembl Genes, H-InvDB Genes, 
RefSeq Genes, UCSC Known Genes, and Vega Genes. The information sources and 
annotating strategies of each human genome annotation are summarized as follows: 
AceView Genes [121]—The AceView annotation was downloaded from its 
website. The data sources of the AceView genes are mRNA sequences from GenBank 
and RefSeq as well as single pass cDNA sequences from dbEST and Trace. It 
summarizes all sequences into a comprehensive evidence-based gene annotation. It is a 
fully automatic process and uses heuristics to closely reproduce manual curation. 
Ensembl Genes [122]—The Ensembl annotation was downloaded from its FTP 
site. The data sources of the Ensembl genes include (1) the automated Ensembl gene 
annotation pipeline “genebuild,” (2) manually curated genes from the Havana Group at the 
WTSI, and (3) consensus coding sequences (CCDS). The final Ensembl genes result from 
clustering and merging these data sources. 
H-InvDB Genes [123]—The H-InvDB annotation was downloaded from its 
website. H-InvDB genes are collected from six high-throughput sequencing projects 
[124]. It uses BLAST to map full-length cDNAs to the human genome, and then 
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annotates the genome based on clustering results. It assigns a standardized functional 
annotation to each H-InvDB transcript by manual curation. 
RefSeq Genes [125]—The RefSeq annotation was downloaded from the UCSC 
Table Browser. The data sources of the RefSeq genes include all sequences submitted to 
the International Nucleotide Sequence Database Collaboration (INSDC), which consists 
of DDBJ, ENA, and GenBank. It combines an automatic genome annotation pipeline and 
a significant level of manual curation. 
UCSC Known Genes [126]—The UCSC Known Genes annotation was 
downloaded from the UCSC Table Browser. The data sources of the UCSC known genes 
include protein data from Swiss-Prot / TrEMBL (UniProt) and the associated mRNA data 
from GenBank. It uses a fully automated process to annotate the genome. 
Vega Genes [127]—The Vega annotation was downloaded from its website. The 
Vega database focuses on the browsing and maintenance of manually annotated data, 
including manually curated sequences from Havana, RIKEN, JGI, and Washington 
University. 
Spliced Mapping versus Un-spliced Mapping 
Spliced mapping refers to algorithms that split reads into segments in order to 
accommodate long gaps or introns in a read (e.g., TopHat and MapSplice); whereas un-
spliced mapping refers to algorithms that align entire read sequences (e.g., Bowtie2, 
BWA, and Novoalign). For RNA-seq data, to directly map sequence reads to the 
reference genome, it is necessary to use spliced mapping algorithms because a read may 
map to exon-exon junctions that are equivalent to a long gap in the context of the 
reference genome. For Case Study 1, Impact of Genome Annotation Choice on Feature 
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Quality, I used two spliced mappers, TopHat and OSA, to map sequence reads to the 
human genome with the guidance of various genome annotations. A typical pipeline for 
spliced mapping is shown in Figure 7. TopHat is a spliced mapper that is widely used for 
mapping RNA-seq data to the reference genome [83]. Given a genome annotation, 
TopHat first maps short sequence reads to the reference transcriptome extracted from the 
reference genome, and then attempts to remap the unmapped reads from the previous 
stage to the reference genome. The mapping outputs from the two stages are then merged 
into the final output. If no genome annotation is given, TopHat uses a spliced technique 
(i.e., segmenting entire reads into smaller segments) to directly map sequence reads to the 
reference genome. OSA (Omicsoft sequence aligner) is a new spliced mapper that 
“improves mapping speed four- to ten-fold with better sensitivity and less false positives” 
compared to the TopHat, SoapSplice, and RUM [85]. It implements a similar mapping 




Figure 7:  Typical RNA-seq Spliced Mapping Pipeline. A spliced mapper maps RNA-
seq data to a reference genome with or without the guidance of a genome annotation. 
Different genome annotations define various sets of exon junction information that affect 





Un-spliced mapping algorithms include both gapped alignment and un-gapped 
alignment. Thus, they can be applied to only transcriptomic mapping tasks. Un-spliced 
mapping algorithms output mapping outcome in terms of transcriptomic coordinates. 
Bowtie is one well-known un-spliced, un-gapped mapper.  
In Case Study 4, Impact of Pipeline Choice on Feature Quality, our team extended 
the capability of un-spliced mapping by adding a coordinate translator that facilitates 
translating transcriptomic coordinates into genomic coordinates. With this module, any 
un-spliced mapper can be used for genomic mappings. Figure 8 demonstrates both un-
spliced and spliced RNA-seq mapping pipelines for Case Study 4. 
 
 
Figure 8:  Un-spliced and Spliced RNA-seq Mapping Pipelines. Both pipelines map to 
the MT/rRNA/ERCC (mitochondria, ribosomal RNA, and External RNA Controls 
Consortium RNA spike-in mix) reference first. The un-spliced mapping pipelines 
combine transcriptome and genome mapping results into a single result for quantification 
(left). The spliced mapping pipelines either generate a single human genome mapping 
result or internally combine transcriptome and human genome mapping results into a 
single result for quantification (right). Thus, no additional merging step is required for 





Single-hit Reporting versus Multi-hit Reporting 
Because the length of each sequence read is short (i.e., at the range of 36 bp to 
300 bp for the current Illumina technology) and many repetitive regions exist in the 
human genome, one sequence read may map to multiple locations in the human genome. 
Depending on the algorithmic design and the application, a sequence mapper may report 
one or many alignments for this type of reads. Bowtie2, GSNAP, Novoalign, TopHat, 
and WHAM allow control over the number of reported mappings per read. By default, 
these algorithms typically report a single best mapping location per read. However, some 
quantification algorithms can use information about multiple ambiguous mapping 
locations to improve gene and transcript expression estimation. Thus, in addition to 
single-hit reporting, in Case Study 4, Impact of Pipeline Choice on Feature Quality, we 
also generated mapping results that reported up to 200 mapping locations per read.  
























to transcriptome or 
genome 
Burrows-Wheeler transform and FM-index  
Bowtie2 [75] 
Burrows-Wheeler transform, FM-index-assisted 
seed alignment, dynamic programming  
BWA [38] Burrows-Wheeler transform 
Novoalign Commercial software, algorithm un-published  
RUM [128] 
Uses Bowtie in a multi-phase mapping to 
transcriptome and genome  
WHAM [129] 
Hash-based indexing and bitwise operations for fast 
alignment  
GSNAP [82] Spliced mapping to 




Minimal sampling strategy, oligomer chaining for 
approximate alignment, sandwich dynamic 
programming  
Magic [121, 130] 
Strand-aware seed-and-extend alignment of read 
pairs, with at least 8 exact bases at the end of each 
aligned segment 
MapSplice [84] 
Spliced mapping to 
genome 
Uses Bowtie for alignment, segmented mapping  
OSA [85] 
Two-stage transcriptome and genome alignment, 
segmented mapping  
STAR [39] 
Sequential maximum mappable seed search, and 
seed clustering and stitching  
Subread [131] Segmented seed-and-vote mapping  
TopHat [83] 
Uses Bowtie or Bowtie2 for alignment, segmented 
mapping  
BWA stands for Burrows-Wheeler aligner; RUM, RNA-seq unified mapper; WHAM, Wisconsin's high-
throughput alignment method; GSNAP, genomic short-read nucleotide alignment program; OSA, Omicsoft 






2.2.2   Expression Quantification 
Count-based Quantification versus Model-based Quantification  
Expression quantification algorithms can be roughly categorized into naïve count-
based quantification and model-based quantification. For all case studies, I selected one 
or two representatives from each category and assessed their strengths and weaknesses 
through various experimental settings. 
The most well-known count-based quantification tool is HTSeq. I used the htseq-
count script from the HTSeq package to count the number of reads (or fragments in the 
paired-end sequencing case) that map to each gene as the gene expression estimate. For 
each mapped read or fragment, htseq-count determines the genes to which these reads or 
fragments associate. If a read or a fragment overlaps more than one gene, it provides 
three scenarios to resolve this ambiguous situation. For all case studies, I adopted the 
“intersection-nonempty” scenario if an ambiguity occurs [44]. 
Cufflinks is a popular model-based quantification tool that constructs graphical 
models describing how reads emit from each gene/transcript and estimates gene/transcript 
expression using the maximum likelihood estimation technique. It is capable of both 
assembling transcripts and quantifying gene or transcript expressions. In my case studies, 
I disabled the assembly function and provided the genome annotation GTF file that 
contains description of targeted genes and their structures as a quantification reference. I 
used Cufflinks with default setting except enabling sequencing bias correction and multi-
mapped reads correction [47]. Information from multi-hit reads is important for model-
based quantification tools. These algorithms use multi-hit read information to estimate 
gene or transcript expression more accurately. 
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Transcriptomic Mapping versus Genomic Mapping 
As briefly touched upon in the previous section, RNA-seq data can be mapped to 
either the reference genome or the reference transcriptome. Therefore, some 
quantification algorithms were specifically designed for quantifying genomic mapping 
outputs, while others were designed for quantifying transcriptomic mapping outputs.  
For Case Study 2, Impact of Expression Quantification Choice on Feature 
Quality, I applied Cufflinks, HTSeq, and MISO to quantify gene and transcript 
expression for the sequence alignment reported in genomic coordinates. The Cuffdiff 2 
program in the Cufflinks package produces gene and transcript expression estimates in 
terms of read count and FPKM [90] (i.e., fragments per kilobase of exon per million 
fragments mapped) estimates. The htseq-count program in the HTSeq package generates 
read count estimates only for genes, while MISO provides read count estimates for both 
genes and transcripts. For sequence alignment reported in transcriptomic coordinates, I 
used RSEM, eXpress, and MMSEQ to quantify gene and transcript expression. These 
three quantification algorithms are able to quantify both genes and transcripts and 
produce both read count and FPKM estimates. In addition, RSEM provides in-house 
TPM (i.e., transcripts per million) estimates. For read count estimates, I applied the same 
trimmed mean of M-values normalization method (TMM) [97] to eliminate the effect of 
the normalization factor when computing evaluation metrics. 
Quantification Pipeline Compatibility 
Mapping results from alignment pipelines were not always compatible with 
quantification tools. Cufflinks requires alignment files to be sorted by alignment 
coordinates and multi-hit reads to be annotated with the ‘NH’ tag in the attribute field of 
 35 
the SAM (sequence alignment/map format) file. HTSeq requires that the alignment files 
are sorted by read name and that the ‘NH’ tag is not present in the SAM file. RSEM only 
quantifies transcriptome mapping, i.e., reads mapped and reported in transcriptomic 
coordinates. Moreover, RSEM only handles un-gapped alignments. Thus, filtering is 
required to remove gapped alignments. Because of these requirements, pre-processing 
alignment outputs before quantification is needed. For Case Study 4, Impact of Pipeline 
Choice on Feature Quality, in total, twenty alignment pipelines, including spliced, un-
spliced, single-hit, and multi-hit pipelines, were suitable for count-based quantification. 
Sixteen alignment pipelines were suitable for Cufflinks, and only ten were suitable for 
RSEM. RSEM is specifically designed to work well with the Bowtie alignment tool. 
Thus, we included this embedded mapping and quantification pipeline in RSEM. 
The key characteristics of these quantifiers are summarized in Table 7. 
 
Table 7:  RNA-seq Expression Quantification Tools Studied in Case Study 4. 
 
Expression Quantification Tool 





Count-based; accumulated counts 
Gene 
Magic quantifier (for Magic mapper 
only) [121, 130] 
Gene, Transcript 
Subread featureCounts (for Subread 
mapper only) [132] 
Gene, Transcript 
RUM quantifier (for RUM mapper 




Poisson model; maximum likelihood 
with maximum a posteriori estimates 
using Bayesian inference 
Gene, Transcript 
RSEM [46] 







2.2.3   Expression Normalization 
RNA-seq expression normalization enables inter- or intra-sample comparison. 
Generally, normalization methods correct the library size (i.e., the total number of 
mapped reads in a sample), which is the primary source of inter-sample variability. We 
used seven normalization methods (Table 8):  FPM (fragments per million mapped 
reads), FPKM (fragments per kilobase of gene length per million mapped reads), median, 
upper quartile, RLE (relative log expression), TMM (trimmed mean of M-values), and 
expression index (specific to the Magic pipeline). I describe each of these normalization 
methods in the context of Case Study 4, but they are all applicable to any other 
experimental settings. 
 
Table 8:  RNA-seq Expression Normalization Methods. 
 
Normalization Method Description 
Reads/Fragments Per Million mapped 
reads/fragments (RPM/FPM) [99] 
Scaling by library size 
Reads/Fragments Per Kilobase per Million 
mapped reads/fragments (RPKM/FPKM) 
[90] 
Scaling by library size and gene/transcript length 
Median [99] Scaling by median of all counts 
Upper Quartile (UQ) [99] Scaling by upper quartile of all counts 
Relative Log Expression (RLE) [98] Scaling by median ratio to median library 
Trimmed Mean of M-values (TMM) [97] Scaling by estimate of relative RNA production 
Expression Index (Eindex) [121, 130] 
Magic pipeline only, scaling and thresholding to 




In Case Study 4, Impact of Pipeline Choice on Feature Quality, the raw count of a 
sample is defined as 𝑥𝑠,𝑛,𝑘 where 𝑠 ∈ {𝐴, 𝐵, 𝐶, 𝐷} indicates the sample, 𝑛 = 1 … 𝑁 
indicates the replicate, and 𝑘 = 1 … 𝐾 indicates the gene. For the benchmark dataset in 
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Case Study 4 (will be introduced in detail in Section 2.4.4), N = 4 and K = 55,874. Since 
genes with zero counts contribute negatively to normalization performance, we first 
identified and used only non-zero genes during normalization. Given that the mean of the 






𝑛=1  , 
(1) 
we defined the set of “present” genes to be 
𝐾𝑝 ∈ {𝑘|(?̅?𝐴,∙,𝑘 > 1 ⋁ ?̅?𝐵,∙,𝑘 > 1)⋀?̅?𝐶,∙,𝑘 > 1 ⋀ ?̅?𝐷,∙,𝑘 > 1 } . (2) 
The total count of present genes for a given sample s and replicate n is 
𝑥𝑠,𝑛 = ∑ 𝑥𝑠,𝑛,𝑘𝑘∈𝐾𝑝  , (3) 








𝑛=1𝑠  . 
(4) 





 . (5) 
Similarly, if we define ?̃?𝑠,𝑛 and ?̂?𝑠,𝑛 as the median and upper quartile of counts, 















𝑛=1𝑠  . 
(6) 









 . (7) 
For FPKM normalization, we defined the length of a gene k as ℓ𝑘, which is the 
length of the union of all exons related to the gene as defined by the AceView 
transcriptome. The original formulation of FPKM arbitrarily used scaling factors of 1x10
3
 
for the gene length and 1x10
6
 for total number of mapped reads. In order to maintain 
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comparable dynamic range among all normalization methods, we instead scaled by the 
average gene length and average total count for all present genes. The average length of 




∑ ℓ𝑘𝑘∈𝐾𝑝  . 
(8) 





 . (9) 
TMM and RLE normalizations are similar to the FPM normalization, but 
introduce an extra scaling factor. We used the edgeR package in R to estimate scaling 
factors for each sample and replicate [65, 97]. The TMM method selects a reference 
sequence library from the pool of samples and then calculates gene-wise log expression 
ratios (M-values) and gene-wise average log expression values (A-values) between the 
target library and the reference library. Extreme numbers in M-values and A-values are 
trimmed and the scaling factor for the target library is the weighted average of remaining 
M-values. The RLE method determines a scaling factor by first defining median library 
size as the gene-wise geometric mean across samples and replicates [98]. The median 
ratio of each sequence library to the median library is taken as the scaling factor. TMM 




















2.3   Evaluation of Feature Extraction Pipeline Performance  
To evaluate the performance of feature extraction pipelines in terms of gene or 
transcript expression quality, I designed various evaluation metrics for both sequence 
mapping and expression quantification / normalization results. 
2.3.1   Evaluation Metrics for Sequence Mapping 
I defined two evaluation metrics for sequence mapping outputs. The first metric is 
based on the categorization of read mapping outcomes. For paired-end sequencing, the 
categories include uniquely paired reads, uniquely mapped singletons, non-uniquely 
paired reads, non-uniquely mapped singletons, and unmapped reads. For single-end 
sequencing, the categories are simpler, including only uniquely mapped reads, non-
uniquely mapped reads, and unmapped reads. The second metric is the percentage of the 
number of reads that map to the annotated and un-annotated genomic sequences. 
2.3.2   Evaluation Metrics for Expression Quantification and Normalization  
I designed and defined various evaluation metrics for assessing the quality of gene 
or transcript expression estimates. Most metrics rely on normalized expression, while a 
few are independent of normalization methods. The evaluation metrics include (1) 
accuracy, which measures the gene- or transcript-level deviation between expression 
estimates based on RNA-seq and those based on the predefined ground truth (e.g., 
simulation and qPCR); (2) precision, which measures the gene- or transcript-level 
dispersion of expression estimates across replicate libraries; (3) reproducibility, which 
measures sample-level variation under similar experimental conditions; and (4) 
reliability, which measures gene- or transcript-level intra-sample consistency among 
replicate libraries. 
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Accuracy Measured as Deviation from the Ground Truth 
As illustrated in Figure 9, accuracy describes how close measurements to the 
reference value (or true value). In my case studies, measurements are gene or transcript 
expression extracted from raw RNA-seq data and the reference value can be either 
simulated expression or qPCR-based expression (with the assumption that qPCR is the 
ground truth, which is commonly acknowledged in the bioinformatics community). For 
this metric, smaller deviation indicates higher accuracy. The rest of this section will 
elaborate more on several variants of this metric for different case studies. 
 
 
Figure 9:  Accuracy and Precision of the Measurement System. The accuracy of a 
measurement system describes the closeness of measurements to the true value, and the 
precision of the measurement system captures the repeatability of consecutive 
measurements. The bell curve shows the distribution of many measurements for a single 
quantity. The accuracy depends on the distance between mean measurements of the 





In Case Study 1, Impact of Genome Annotation Choice on Feature Quality, I used 
the mean absolute deviation (MAD) and the root-mean-squared error (RMSE) to quantify 














where FC stands for fold change and n is the number of genes or transcripts in the pool. 
In Case Study 2, Impact of Expression Quantification Choice on Feature Quality, 
I quantified deviation by computing the normalized RMSE between estimated counts 
from quantification pipelines and true counts from simulation. Since RMSE is not scale-
invariant, to adjust the sequencing depth effect, I normalized the RMSE by dividing the 
original RMSE by 10 for 100-million-read cases, by 5 for 50-million-read cases, and by 1 
for 10-million-read cases.  
In Case Study 4, Impact of Pipeline Choice on Feature Quality, we computed 
inter-sample log ratios for each gene for both RNA-seq pipeline-produced gene 
expression and qPCR-produced gene expression, and the deviation was defined as the 
difference between inter-sample log ratios from both sources. The formulation of this 
process is as follows: 
We defined RNA-seq assayed gene expression as 𝑥𝑠,𝑛,𝑘 and qPCR assayed gene 
expression as 𝑦𝑠,𝑛,𝑘 where 𝑠 ∈ {𝐴, 𝐵, 𝐶, 𝐷} indicates the sample, 𝑛 = 1 … 𝑁 indicates the 
replicate, and 𝑘 = 1 … 𝐾 indicates the gene (for the PrimePCR set, N = 1; K = 10,222). 






𝑛=1  . 
(13) 
Given samples A and B, the absolute log-ratio deviation between RNA-seq-based 







) − 𝑙𝑜𝑔2 (
?̅?𝐴,∙,𝑘
?̅?𝐵,∙,𝑘
)| , (14) 
 
and the final deviation was defined as the median of all ΔA
B
,k
, 𝑘 = 1 … 𝐾. 
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Precision Measured as Variation across Replicate Libraries 
As also illustrated in Figure 9, precision describes the dispersion of multiple 
measurements for the same quantity. Since gene expression differs by orders of 
magnitude, statistics that capture normalized dispersion are needed. One popular statistic 
that fits this objective is the coefficient of variation (CoV), which is defined as the ratio 
between the standard deviation and the mean of replicate measurements. For this metric, 
smaller CoV indicates higher precision. Note that this metric will only work when 
replicate libraries are available. The rest of this section will elaborate more on several 
variants of this metric for different case studies. 
In Case Study 1, Impact of Genome Annotation Choice on Feature Quality, I 
removed genes that are absent (i.e., have zero expression) in all replicate libraries, 
calculated CoV for each remaining gene, and finally computed average CoV across all 











where Si and 𝑥?̅? are the sample standard deviation and mean of expression estimates 
across replicate libraries with the same biological condition, respectively, and n is the 
number of targeted genes or transcripts. I applied the same metric to different sets genes 
and transcripts in Case Study 1. 
In Case Study 2, Impact of Expression Quantification Choice on Feature Quality, 
I computed the condition-wise CoV for each gene and then summarized these CoVs into 
the gene-wise CoV. The same technique applies to the transcript-wise CoV analysis. 
In Case Study 4, Impact of Pipeline Choice on Feature Quality, we computed the 





 , (16) 
where 𝑘 = 1 … 𝐾 indicates the gene, and 𝑠 ∈ {𝐴, 𝐵, 𝐶, 𝐷} indicates the sample. We only 
consider K = 10,222 genes that were expressed as non-zero in all conditions. We then 
computed the median of all CoV derived from all genes and all samples as the final 
measure of precision. 
Metric based on Concepts of Accuracy and Precision 
In Case Study 2, Impact of Expression Quantification Choice on Feature Quality, 
I calculated the gene-wise CoV across all replicate libraries for the simulated dataset that 
serves as the ground-truth measurement for replicate variation. I then examined the 
percent error when comparing the gene-wise CoV from various quantification pipelines 
with that from the simulated dataset. Finally, I counted the cumulative number of genes 
or transcripts with percent errors of the CoV from 0% to 5%, from 0% to 10%, from 0% 
to 15%, and so on, up to from 0% to 100%. The same technique applied to the transcript-
wise CoV analysis. 
Reproducibility Measured as Inter-sample Correlation 
According to the definition described in [133], reproducibility refers to “the 
variation in measurements made on a subject under changing conditions.” The changing 
conditions may involve with different instruments for measurements, different 
measurement time points, different observers, and many other factors. In the context of 
my case studies, since no two replicate libraries of RNA-seq are exactly identical to each 
other due to various biological, chemical, instrumental, and experimental factors, the 
assessment of variation between replicate libraries falls within the scope of 
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reproducibility. I chose to use the inter-sample Spearman correlation coefficient as the 
measure of reproducibility, which is a commonly applied metric for reproducibility. 
Higher Spearman correlation coefficients indicate higher reproducibility.  
This metric was applied to only Case Study 4, Impact of Pipeline Choice on 
Feature Quality. In Case Study 4, we computed the pairwise Spearman correlation 
coefficient between replicate libraries for the same sample s, 𝑠 ∈ {𝐴, 𝐵, 𝐶, 𝐷}. Since each 
sample has four replicate libraries, there are six pairwise comparisons for each sample 
and 24 comparisons in total for the entire dataset. We then computed the median of all 24 
Spearman correlation coefficients as the final measure of reproducibility. 
Reliability Measured as Intraclass Correlation 
The reliability of a measurement system can be assessed by the intraclass 
correlation coefficient (ICC) [133, 134]. Conceptually, ICC is applicable to 
measurements that can be organized into groups, and it describes how similar 
measurements of the same group are to one another. Modern ICC definition borrows the 
framework of analysis of variance (ANOVA), or more specifically ANOVA with random 
effects [134]. The type of ANOVA depends on the experimental design and generally 
follows the definition in [134]. ICC(1,1) and ICC(1,k) are based on the one-way random 
effects model and are applicable to the case that each group is assessed by a different set 
of k raters randomly selected from a larger population of raters. ICC(2,1) and ICC(2,k) 
are based on the two-way random effects model and are applicable to the case that a 
random sample of k raters is preselected from a larger population and each rater assesses 
each group exactly once (i.e., each rater assesses n groups altogether). ICC(3,1) and 
ICC(3,k) are based on the two-way mixed effects model and are applicable to the case 
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that each group is assessed by each of the same k raters, who are the only raters in the 
population. The second parameter in ICC([1,2,3],[1,k]) denotes whether the ICC is to 
measure the reliability of a single measurement or the average of k measurements.  
For my case studies with replicate libraries for each sample, ICC(1,1) or ICC(1,k) 
fitted my objective since for a specific gene g, gene expression of replicate libraries for 
different samples (or different groups in the previous context) were not assessed under 
exactly the same conditions (or assessed by the same raters in the previous context). 
Finally, ICC(1,k) was my final choice since replicate libraries are available for most 
experiments. Mathematically, a one-way random effects model can be formulated as  
𝑌𝑖𝑗 = 𝜇 + 𝛼𝑗 + 𝜖𝑖𝑗 , (17) 
where 𝑌𝑖𝑗 is the i
th
 observation in the j
th
 group, 𝜇 is an unobserved overall mean, 𝛼𝑗 is the 
group-specific random effect with zero mean and variance 𝜎𝛼
2, and 𝜖𝑖𝑗 is an unobserved 
noise term with zero mean and variance 𝜎𝜖





where BMS stands for the between groups mean square and has the expected mean square 
of 𝑘𝜎𝛼
2 + 𝜎𝜖
2, and WMS stands for the within group mean square and has the expected 
mean square of 𝜎𝜖
2. Higher ICC indicates higher reliability.  
This metric was applied to only Case Study 4, Impact of Pipeline Choice on 
Feature Quality. In Case Study 4, we calculated ICC for each gene, and then computed 
the median of all ICCs as the final measure of reliability. 
2.4   Case Study 
To demonstrate my approach for quality control for precision medicine, I detail 
four case studies in this section, including the impact of genome annotation, expression 
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quantification, normalization, and the overall pipeline choice on feature (i.e., gene or 
transcript expression) quality. The background, experimental design, datasets, and results 
of each case study are discussed based on their original publications [114-118]. 
2.4.1   Impact of Genome Annotation Choice on Feature Quality 
2.4.1.1   Background 
RNA-seq is a major branch of the NGS technology that studies the transcriptome 
[135]. One aspect of transcriptomic research is quantification of expression levels for 
various genomic elements such as genes and transcripts [90]. Acquiring a transcriptomic 
expression profile requires knowledge about the location of genomic elements in the 
context of the reference genome, and such the knowledge is provided by a process called 
genome annotation. Multiple human genome annotations are publicly available, 
including, but not limited to, the AceView database [121] and the RefSeq database [125]. 
Thus, it is necessary to study the impact of genome annotation choice on gene or 
transcript expression quality derived from RNA-seq data. 
Genome annotation is a dynamic process that defines coordinates for each 
genomic element with respect to the genome sequence. Such a process bridges the gap 
between DNA or RNA sequences and biological functions [136]. Integration of a genome 
annotation with mapping information from RNA-seq short sequence reads enables 
quantification of genomic elements. Each genome annotation project adopts different 
annotation strategies and information sources. Thus, high variation exists among publicly 
available annotations in terms of the comprehensiveness of annotated genomic elements. 
Some annotation strategies rely on computer-based prediction, resulting in more complex 
gene models that contain more putative genomic elements. Other annotation strategies 
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rely on evidence-based methods, that is, methods that require more manual curation, 
leading to simpler gene models with a fewer number of genes and transcripts. 
I compared six human genome annotations from various databases, including the 
AceView database [121], the Ensembl database [122], the H-InvDB database [123], the 
RefSeq database [125], the UCSC Known Genes database [126], and the Vega database 
[127]. The key characteristics of each genome annotation are summarized in Table 9, in 
which annotations are ordered by decreasing complexity from left to right. The term 
“complexity” describes the primary differentiating characteristic among the genome 
annotations. I defined the complexity of a human genome annotation to be proportional to 
the number of genes, transcripts, and exons. This definition enabled me to investigate the 
relationship between the measure of genome annotation complexity and the outcome of 
the RNA-seq expression analysis pipeline. I hypothesized that a more complex genome 
annotation is more difficult for RNA-seq mapping and quantification because of the 
difficulties of determining a best possible mapping from multiple candidate mappings 
and assigning unresolved ambiguous mappings to their correct genomic elements. 
Any relationship between genome annotation complexity and gene expression 
quality could be informative in guiding the selection of a genome annotation for various 
gene / transcript expression-based studies using RNA-seq data. Currently no guidelines 
for selecting a genome annotation for RNA-seq expression analysis are available, and the 
effect of genome annotation choice on downstream data analysis is still unclear. The 
focus of this study was to obtain some insights into the impact of human genome 
annotation choice on RNA-seq expression estimates. 
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Table 9:  Properties of Various Human Genome Annotations. 
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# of Genes 72,376 43,893 48,817 44,880 28,423 23,731 
# of Transcripts 259,426 236,861 177,858 158,835 75,725 41,099 
# of Exons 678,503 542,099 534,400 493,509 273,711 227,710 
Average # of Transcripts per 
Gene 
3.58 5.40 3.64 3.54 2.66 1.73 
Maximum # of Transcripts per 
Gene 
119 885 82 77 129 77 
Annotated Percentage (%) 
Gene 52.93 45.09 49.61 48.29 44.28 40.17 
Exon 5.70 3.72 3.63 3.53 2.70 2.27 
Coding Sequence 1.71 1.43 1.14 1.05 1.13 1.07 
The annotated percentage is the total length of all genomic elements (gene, exon, or coding sequence) over 




2.4.1.2   Experimental Design 
This case study aims to provide insights into the effect of different choices of the 
human genome annotation on the variation in RNA-seq expression estimates. I proposed 
a complexity measure (referring to the previous section) that relates observations in 
downstream RNA-seq analysis to the trend of genome annotation characteristics. The 
typical pipeline for RNA-seq expression analysis includes sequence mapping, expression 
quantification, expression normalization, and calling DEGs. As shown in Figure 10, in 
this case study, I used two publicly available RNA-seq datasets that provide a list of 
DEGs and qPCR validation information. I mapped short sequence reads to the human 
reference genome with two spliced mappers, OSA [85] and TopHat [83]. Alignment 
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outputs of both tools were quantified by htseq-count [44] to acquire gene expression 
estimates in terms of the read counts. Since OSA has embedded quantification and TPM 
normalization [46] in its package, I used Cufflinks [47] to quantify TopHat alignment 
outputs only and then obtained gene / transcript expression in terms of FPKM-normalized 
values [90]. Given the read counts data from htseq-count, I applied the edgeR package in 
R [65] to call DEGs between treatment and control samples. For TPM or FPKM 
expression estimates, I calculated fold changes between treatment and control samples 
and then compared these fold changes to external qPCR validation results provided by 
the original studies. I proposed several evaluation metrics for each analytical step to 




Figure 10:  Workflow for Chapter 2, Case Study 1. The five dashed boxes correspond 
to five steps in the RNA-seq data analysis pipeline. I applied two sequence mapping tools 
and two expression quantification tools to estimate gene / transcript expression with 
normalization methods of count, TPM, or FPKM. The fold-change method and the edgeR 
tool were used to infer DEGs. At each analytical step, I assessed variations resulting from 






2.4.1.3   Datasets 
I downloaded two publicly available RNA-seq datasets from the NCBI Sequence 
Read Archive (SRA) repository. The first dataset (accession number:  SRP008482) 
investigates how thrombin treatment affects endothelial function in terms of gene 
expression profiles. In general, thrombin can stimulate endothelial cells and regulate the 
expression, release and activation of a number of biological mediators [137]. The targeted 
biological samples are “human pulmonary microvascular endothelial cells (HMVEC-L)” 
with two conditions—control (two technical replicates) and thrombin treatment for six 
hours (three technical replicates). The sequencing platform was Illumina HiScanSQ with 
the sequencing depth at about 50 million read pairs for each technical replicate and the 
read length of 101 bp. The study also validated expression fold changes of three genes 
(CELF1, FANCD2, and TRAF1) between treated and control samples using a qPCR 
assay. Such qPCR information is considered the ground truth and is useful for validating 
and evaluating RNA-seq expression estimates. 
The second dataset (accession number:  SRP000727) studies alternative transcript 
regulation in human tissue transcriptomes [138]. It profiled 16 tissue transcriptomes, and 
two MAQC (microarray quality control) samples were included in the study. The two 
MAQC samples are Ambion Human Brain Reference RNA (HBRR) and Stratagene 
Universal Human Reference RNA (UHRR). The study includes four technical replicates 
for the HBRR sample and 3 technical replicates for the UHRR sample. This is an older 
sequencing dataset which used Illumina Genome Analyzer to generate single-end reads 
with the read length of 36 bp. Each technical replicate has only 2.5 million reads. The 
merit of this dataset is that the qPCR results are publicly available through the MAQC 
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project. Fold changes of 1,044 genes from the TaqMan qPCR assay again provide an 
external ground truth for evaluating RNA-seq expression estimates. 
2.4.1.4   Results and Discussion 
Complexity of human genome annotations 
Table 9 summarizes several important statistics for each genome annotation. I 
ranked the genome annotation based on the number of genes, transcripts, and exons. 
Ranking the set of human genome annotations (i.e., AceView, H-InvDB, Ensembl, Vega, 
UCSC, and RefSeq) by decreasing number of genes resulted in ranks of (1, 4, 2, 3, 5, and 
6). In other words, AceView was ranked at 1 because it had the most number of genes, 
while H-InvDB was ranked at 4. Similarly, ranking the set of human genome annotations 
by decreasing number of transcripts and exons resulted in identical ranks of (1, 2, 3, 4, 5, 
and 6) and (1, 2, 3, 4, 5, and 6), respectively. I then defined the complexity rank of the 
genome annotation to be proportional to the average of these three ranks. The average 
ranks of these genome annotations are (1, 2.67, 2.67, 3.67, 5, and 6). I used the mode of 
ranks to break ties (e.g., the H-InvDB and Ensembl annotations both ranked 2.67). Thus, 
the human genome annotations were ordered by decreasing complexity as AceView, H-
InvDB, Ensembl, Vega, UCSC, and RefSeq. The annotated percentage of each genome 
annotation generally follows the trend of complexity as demonstrated in Figure 11. For 
the average number of transcripts per gene and the maximum number of transcripts per 
gene, annotations generally have the same trend as the complexity measure. However, the 
H-InvDB annotation deviates from this trend, containing on average 50% more 




Figure 11:  Annotated Percentage per Chromosome. For each genome annotation, the 
annotated percentage of each chromosome is demonstrated on (a) the gene level, (b) the 
exon level, and (c) the coding sequence level. The AceView annotation usually has the 




Effect of human genome annotation complexity on mapping 
I proposed two metrics to assess the effect of genome annotation complexity on 
sequence mapping. I first examined read mapping information and classified them into 
three categories for single-end sequencing samples or into five categories for paired-end 
sequencing samples. I used OSA alignment outputs as an example to demonstrate the 
impact of genome annotation choice on read mapping. For both the shorter read length 
single-end sequencing samples (1×36 bp; SRP000727) and the longer read length paired-
end sequencing samples (2×100 bp; SRP008482), I observed similar results (Figure 12). 
The RefSeq annotation consistently had the highest percentage of uniquely mapped reads 
and uniquely paired reads in the single-end case and paired-end case, respectively. Note 
that the percentage of unmapped reads was similar for all annotations. The percentage of 
non-uniquely mapped reads or read pairs increased as the genome annotation becomes 
more complex. Outlying cases existed (e.g., the Vega annotation had the lowest 
percentage of uniquely paired reads in paired-end sequencing samples), but the observed 
trend still followed the complexity measure. From Table 9, more complex annotations 
generally annotate more genes and transcripts, and thus, they increase the possibility of 
ambiguous mappings. These ambiguous mappings are more difficult to resolve for 
identifying the best mapping, which directly translates to the increase in the percentage of 








Figure 12:  Distribution of Read Mapping Categories. (a) MAQC samples (SRA:  
SRP000727) contain single-end reads, and thus, there are three read mapping 
categories—uniquely mapped reads, non-uniquely mapped reads, and unmapped reads. 
(b) Thrombin study samples (SRA:  SRP008482) contain paired-end reads, and thus, five 
read mapping categories can possibly occur. Cases of uniquely paired reads and non-
uniquely paired reads occur when both ends of a read pair mapped to a reference genome. 
Situations of uniquely mapped singletons and non-uniquely mapped singletons occur 
when only one end of a read pair mapped to the reference genome. The RefSeq 
annotation has the highest percentage of uniquely mapped reads and the lowest non-




I then examined the percentage of reads that mapped to the annotated and un-
annotated genomic sequences. More reads mapping to the annotated genomic sequences 
implies that more information will be available for the quantification step. From Figure 
13, I observed that the AceView annotation resulted in the highest percentage of reads 
that map to annotated sequences. In contrast, the UCSC and RefSeq annotations had 
lower percentages of reads that map to annotated sequences, with UCSC being the 




Figure 13:  Percentage of Reads Mapping to Annotated/Unannotated Regions. 
Panels (a) – (d) represent different combinations of samples (top—MAQC samples; 
bottom—thrombin study samples) and spliced mappers (left—OSA; right—TopHat). The 
UCSC annotation usually has the lowest percentage of reads that mapped to the annotated 
genomic sequences, while the AceView annotation usually has the highest percentage. 
The same observation is applicable to all four combinations of samples and mappers. 
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Effect of human genome annotation complexity on quantification 
I proposed two metrics to assess the impact of genome annotation complexity on 
RNA-seq quantification. The first metric was to evaluate the stability of gene and 
transcript expression estimates. Figure 14 demonstrates the variation of average CoV due 
to the choice of the genome annotation and the selection of gene or transcript subgroups. 
I focused on four subgroups—all genes of each annotation, common genes (13,613 genes 
for the OSA pipeline and 13,810 genes for the TopHat-Cufflinks pipeline) that are 
defined in all annotations, genes not common to all annotations (i.e., uncommon genes), 
and all transcripts. Trends for all genes and uncommon genes were similar. The AceView 
annotation had the highest average CoV, followed by the Vega annotation, the Ensembl 
annotation, the H-InvDB annotation, the UCSC annotation, and the RefSeq annotation. In 
the case of all transcripts, sometimes the H-InvDB annotation resulted in the highest 
average CoV. For common genes, the difference in average CoV among various 
annotations was not significant. The RefSeq annotation always resulted in the lowest 
average CoV, whereas the H-InvDB or AceView annotations had the highest average 
CoV. The variation between annotations became larger for the cases of all genes, 
uncommon genes, and all transcripts since more annotation-specific elements were being 
considered. More complex annotations are more challenging for quantification because a 
larger number of ambiguous mappings occur. Note that Ensembl and Vega deviated from 
the trend of the annotation complexity measure. A possible rationale for this observation 
was that the Ensembl and Vega annotations tended to include more small RNAs 
compared with the other annotations. Since the sequencing data I analyzed follows the 
poly(A)-enrichment library preparation protocol, ideally, only mRNAs were retained in 
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the final sequencing libraries. Thus, the majority of small RNAs should have zero or very 
low expression. I defined these zero expressing elements as absent genomic elements. 
The inclusion of low-expressing genomic elements in the Ensembl or Vega annotation 




Figure 14:  Average CoV for Various Annotations and Gene / Transcript Sets. 
Panels (a) – (d) represent different combinations of samples (top—MAQC samples; 
bottom—thrombin study samples) and expression estimates (left—TPM estimates from 
OSA package; right—FPKM estimates from TopHat alignment with Cufflinks 
quantification). The RefSeq annotation always has the smallest average CoV, while the 
AceView annotation has the highest average CoV for most of the cases. The variation is 






Figure 15 demonstrates that the percentage of present genomic elements depends 
on the annotation. I defined a “present” genomic element to be an element that has 
nonzero expression for at least one technical replicate. For common genes, all annotations 
had a similar percentage of present genes. For uncommon genes, all genes, and all 
transcripts, the relation among the AceView, H-InvDB, Ensembl, and Vega annotations 
was more uncertain compared with other evaluation metrics. In most cases, the H-InvDB 
annotation had a higher percentage of present genes / transcripts than the AceView 
annotation. The RefSeq annotation always had the highest percentage of present genes / 
transcripts, followed by the UCSC annotation. As I explained in the previous paragraph, 
more small RNAs are included in the Ensembl and Vega annotations. Because of the 
poly(A)-enrichment library preparation, most of these small RNAs had zero expression 
and were identified as absent, which correspondingly decreased the percentage of present 













Figure 15:  Present Percentage for Various Annotations and Gene / Transcript Sets. 
Panels (a) – (d) represent different combinations of samples (top—MAQC samples; 
bottom—thrombin study samples) and expression estimates (left—TPM estimates from 
OSA package; right—FPKM estimates from TopHat alignment with Cufflinks 
quantification). The RefSeq annotation usually has the highest percentage of present 
genomic elements, while the Ensembl or Vega annotation generally has the lowest 





Effect of annotation complexity on differential expression calling 
Three genes were validated by a qPCR assay for the thrombin study samples. I 
examined the difference between RNA-seq-based fold changes and qPCR-based fold 
changes and summarized the results in Table 10. From Table 10, I observed that the 
UCSC annotation always outperformed RefSeq annotation in terms of MAD from the 
qPCR fold-change estimates. However, the difference between them was not significant. 
In contrast, AceView and H-InvDB annotations had relatively higher MAD. Such the 
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observation leads to a conclusion that more complex annotations increase the difficulty of 
acquiring accurate gene expression estimates. Higher variations in gene expression 
estimates propagate to fold-change estimates. 
 





RNA-seq TPM-Normalized Expression Estimates (FC) 
AceView H-InvDB Ensembl Vega UCSC RefSeq 
TRAF1 2.862 3.029 3.034 3.025 2.998 2.934 2.922 
FANCD2 -1.050 -0.782 -0.687 -0.888 -0.856 -0.840 -0.840 
CELF1 -0.202 -0.138 -0.202 -0.098 -0.098 -0.239 -0.275 
MAD between  
qPCR & RNA-seq  




RNA-seq FPKM-Normalized Expression Estimates (FC) 
AceView H-InvDB Ensembl Vega UCSC RefSeq 
TRAF1 2.862 3.874 3.845 3.797 3.719 3.677 3.674 
FANCD2 -1.050 0.057 0.057 -0.345 -0.322 -0.202 -0.151 
CELF1 -0.202 0.642 0.516 0.595 0.585 0.390 0.356 
MAD between  
qPCR & RNA-seq  
0.987 0.936 0.812 0.791 0.751 0.756 





The qPCR data for MAQC samples are publicly available. I used three statistics to 
assess variations due to the genome annotation choice. As shown in Figure 16, less 
complex genome annotations (e.g., the RefSeq annotation) result in lower MAD, lower 
RMSE, and higher correlation coefficients when comparing RNA-seq fold-change 
estimates to qPCR fold-change estimates. Some outlying cases existed (e.g., the Ensembl 
annotation had the highest RMSE when using FPKM expression estimates), but the 
general trend of this evaluation metric still followed the annotation complexity measure. 
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Figure 16:  Statistics for Fold-Change Comparisons. The comparison of fold-change 
estimates between RNA-seq and qPCR using two RNA-seq expression estimates and 
three statistics. (a) TPM estimates are produced by the OSA package. (b) FPKM 
estimates are generated by Cufflinks with TopHat alignment. The RefSeq annotation 
always has the lowest mean absolute deviation, the lowest root-mean-square error, and 




2.4.1.5   Summary of Case Study 
The genome annotation is a necessary component for RNA-seq expression 
analysis. Multiple genome annotations are publicly available; however, it is not clear how 
different choices of the genome annotation will affect downstream RNA-seq expression 
estimates. In this case study, I defined the complexity of the human genome annotation 
and assessed the relationship between genome annotation complexity and several RNA-
seq performance metrics. Based on my complexity measure, I ordered existing human 
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genome annotations from most to least complex as follows—AceView, H-InvDB, 
Ensembl, Vega, UCSC, and RefSeq. In more complex annotations, a higher percentage of 
the entire genome is annotated. For RNA-seq sequence mapping, less complex 
annotations resulted in a higher percentage of uniquely mapped reads and uniquely 
mapped read pairs for both single-end and paired-end samples. However, at the same 
time, the number of RNA-seq reads mapping to annotated genomic sequences was 
smaller for less complex annotations. Genome annotation complexity also affected RNA-
seq expression estimates. More complex annotations resulted in more ambiguous 
mappings, which increased the difficulty of RNA-seq quantification and caused higher 
expression variation among RNA-seq replicate libraries. Furthermore, more complex 
annotations led to a lower percentage of present (i.e., detected) genes or transcripts, 
which suggests that the putative genomic elements in these annotations tend to be non-
expressers or low expressers. Deviations in RNA-seq expression estimates due to 
differences in genome annotation complexity can propagate to fold-change statistics and, 
subsequently, differential expression detection. When comparing RNA-seq fold-change 
statistics to ground-truth qPCR fold-change statistics, more complex annotations tended 
to have larger deviation and smaller correlation. In summary, the impact of genome 
annotation choice on RNA-seq expression estimates is significant, and the choice of 
annotation should depend on the objective of an application. Less complex genome 
annotations are preferable for applications that require more stable RNA-seq expression 
estimates. However, to discover and explain unknown biological mechanisms, more 
comprehensive and complex genome annotations may be necessary. 
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2.4.2   Impact of Expression Quantification Choice on Feature Quality 
2.4.2.1   Background 
A single RNA-seq run can produce millions of sequence reads. Focusing on 
RNA-seq transcriptome profiling, a standard data analysis pipeline includes sequence 
mapping, expression quantification and normalization, and various downstream 
inferences. Expression quantification algorithms attempt to uniquely assign sequence 
reads to genes or transcripts. However, this is a challenging process since (1) alternative 
spliced transcripts of a gene share exons and (2) sequence reads may map to multiple loci 
due to the relatively short read length and high similarity among some genomic regions 
[72]. These challenges result in read assignment uncertainty.  
To address these challenges, researchers have developed a number of 
quantification algorithms. Several (e.g., HTSeq [44] and BEDTools [45]) simplify the 
problem by counting the number of sequence reads aligned to a targeted gene with a 
predefined gene model, and others (e.g., Cufflinks [47] and RSEM [46]), which 
potentially resolve the multi-mapping issue, build upon the Poisson-based model and 
probabilistically assign sequence reads to transcripts or genes. Quantification algorithms 
can be classified into two categories in terms of the input information from the sequence 
alignment. Some require sequence alignment to be reported in genomic coordinates while 
others require sequence alignment to be reported in transcriptomic coordinates.  
Because of various characteristics of quantification algorithms, I proposed an 
approach for systematically assessing the performance of these algorithms using both 
simulated and real datasets.  
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2.4.2.2   Experimental Design 
The workflow of this case study is shown in Figure 17. Data sources included 
one simulated dataset and two real datasets. I mapped sequence reads of these datasets to 
the UCSC hg19 reference genome using TopHat [83] either with or without external 
genome annotation information (the GTF file) and to the RefSeq reference transcriptome 
using Bowtie [73]. I then used Cufflinks [47], HTSeq [44], and MISO [88] to quantify 
sequence alignments reported in genomic coordinates, and RSEM [46], eXpress [139], 
and MMSEQ [140] to quantify those reported in transcriptomic coordinates. Finally, I 
computed gene and transcript read counts from the simulated dataset as the ground truth, 
and investigated the performance of various quantification algorithms. 
 
 
Figure 17:  Workflow for Chapter 2, Case Study 2. This case study includes three 
RNA-seq datasets—one simulated and two real. Depending on sequence mapping 
outputs, some quantifiers (e.g., Cufflinks, HTSeq, and MISO) are designed to handle 
mapping outputs in genomic coordinates, while some others (e.g., RSEM, eXpress, and 
MMSEQ) are designed to handle mapping outputs in transcriptomic coordinates. With 
true expression derived from the simulated dataset and estimated expression generated by 
the six quantifiers for the three datasets, I designed various metrics to assess the 
performance of each quantification pipeline. 
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2.4.2.3   Datasets 
To create the simulated dataset, I used Flux Simulator [141] to produce a gene 
expression profile and then used the same expression profile to generate three technical 
replicates with the read length of 2×100 bp for each sequencing depth (i.e., 10, 50, and 
100 million read pairs). In Flux Simulator, multiple library preparation and sequencing 
steps introduced variations among the technical replicates. 
I also downloaded two publicly available datasets from the NCBI SRA repository. 
The first dataset, which contains three thrombin-treated samples and two control samples, 
studied the effect of thrombin on endothelial function (SRA accession:  SRP008482 
[137]). Using the Illumina HiSeq 2000 platform, the authors sequenced these samples, 
each of which has around 50 million 2×100 bp read pairs. The second dataset, which 
contains four treatments, each with two replicates, investigated the off-target effect of 
EGFP siRNA and pro-siRNA in the HeLa-d1EGFP cell line (SRA accession:  
SRP018552 [142]). Using the Illumina Genome Analyzer II platform, the authors 
sequenced these samples, each with about 25 million 50 bp single-ended reads. 
2.4.2.4   Results and Discussion 
For this case study, I proposed three assessment metrics to investigate the 
performance of quantification algorithms. Figure 18, panel A and Figure 19, panel A 
show that normalized RMSE varies according to the quantification strategy and the 
sequencing depth. A lower normalized RMSE indicates smaller deviation between 
estimated and true expression. Note that the high sequencing depth (e.g., 100M read 
pairs) does not improve significantly in the normalized RMSE. Figure 18, panel B and 
Figure 19, panel B demonstrate that the number of genes / transcripts falling within 
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predefined percent errors of the CoV differs according to the quantification strategy. 
Curves closer to the upper-left corner of the figure indicate a closer measure of variation 
to the ground truth. Figure 20 and Figure 21 use box plots to illustrate that the 
distribution of the gene-wise or transcript-wise CoV also varies according to the 
quantification strategy in the real RNA-seq datasets. Lower CoV indicates a smaller 
variation among the technical replicates, which is the desired property. 
 
 
Figure 18:  Gene Expression Quantification Performance for the Simulated Data. 
Gene-level performance metrics for the simulated RNA-seq dataset includes (A) the 
normalized RMSE and (B) the percentage error of the CoV. TopHat T denotes genome 
alignment using TopHat with external GTF information; TopHat G denotes genome 
alignment using TopHat without external GTF information; and Bowtie represents 







Figure 19:  Transcript Expression Quantification Performance for the Simulated 
Data. Transcript-level performance metrics for the simulated RNA-seq dataset includes 
(A) the normalized RMSE and (B) the percentage error of the CoV. TopHat T denotes 
genome alignment using TopHat with external GTF information; TopHat G denotes 
genome alignment using TopHat without external GTF information; and Bowtie 











Figure 20:  Expression Quantification Performance for the SRP008482 Data. The 
distribution of the CoV varies according to the quantification strategy for both gene- and 
transcript-level expression estimates using the SRP008482 dataset. TopHat T denotes 
genome alignment using TopHat with external GTF information; TopHat G denotes 
genome alignment using TopHat without external GTF information; and Bowtie 










Figure 21:  Expression Quantification Performance for the SRP018552 Data. The 
distribution of the CoV varies according to the quantification strategy for both gene- and 
transcript-level expression estimates using the SRP018552 dataset. TopHat T denotes 
genome alignment using TopHat with external GTF information; TopHat G denotes 
genome alignment using TopHat without external GTF information; and Bowtie 





My results suggest that genome alignment with external GTF information 
(denoted as TopHat T) resulted in smaller deviations and lower CoVs than that without 
GTF information (denoted as TopHat G). This observation held for Cufflinks, HTSeq, 
and MISO with the three metrics, shown in Figure 18, Figure 19, Figure 20, and Figure 
21. Without external GTF information, TopHat searches for candidate mapping locations 
in the entire genome, which may increase the odds that a sequence read maps to an 
incorrect location. When focusing on expression-based applications, if the GTF file is 
available, I recommend using GTF-guided alignment to speed up the computational 
process and increase the expression estimation accuracy.  
Another key finding was that quantification algorithms based on transcriptome 
alignment tended to result in smaller deviations than genome alignment when using 
simulated expression as the reference, with eXpress being an outlier (Figure 18, panel A 
and Figure 19, panel A). The analysis of real RNA-seq datasets showed that 
transcriptome alignment also resulted in a comparable or lower CoV across technical 
replicates than genome alignment (Figure 20 and Figure 21). The difference became 
more significant in the transcript-wise CoV analysis. However, for the percent error of 
the CoV, quantification algorithms based on genome alignment, such as Cufflinks and 
HTSeq, outperformed all other quantification algorithms, with RSEM being tied with the 
Cufflinks TopHat G quantification strategy (Figure 18, panel B and Figure 19, panel B). 
Based on these observations, I infer that quantification algorithms based on genome 
alignment may cause greater absolute deviation but maintain relative variation among 
technical replicates. Even though the observations were not exactly consistent, 
quantification algorithms based on transcriptome alignment generally performed better in 
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terms of the three metrics, with RSEM outperforming others in all cases. The possible 
reason is that transcriptome alignment preserves direct mapping information about each 
transcript while genome alignment does not. Thus, while genome alignment requires 
additional effort to assign reads to one of the transcripts of a gene, transcriptome 
alignment requires only the identification of chimeric mappings in multi-mapping cases.  
My study identified several outlying cases. For one, with three evaluation metrics, 
the MISO package performed worse (i.e., a greater deviation and a higher CoV) in most 
of the cases, which may have been due to MISO ignored too much information, such as 
(1) read pairs mapped to the same strand and (2) reads that have no paired mate. 
Moreover, Bayesian-based algorithms (e.g., MISO and eXpress) tended to introduce 
higher variation in expression estimates. I hypothesized that Bayesian-based approaches 
heavily depend on the prior distribution. Thus, if algorithms cannot converge within a 
predefined number of iterations, the expression estimates may have been only a 
suboptimal solution. This hypothesis was partially confirmed by the high sensitivity of 
eXpress to the “forgetting factors” discussed in [139]. 
2.4.2.5   Summary of Case Study 
I proposed an approach that includes three alignment strategies and six 
quantification algorithms for assessing RNA-seq quantification algorithms in replication 
studies using both simulated and real RNA-seq datasets. By examining multiple metrics, I 
found that the TopHat T alignment strategy always outperformed the TopHat G 
alignment strategy. In addition, quantification algorithms using sequence alignment 
reported in transcriptomic coordinates usually resulted in a smaller deviation and a lower 
CV, with eXpress being the outlier. Furthermore, RSEM consistently performed better 
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compared with other quantification algorithms. My approach is useful for 
comprehensively assessing new RNA-seq quantification algorithms. Based on my results, 
I suggest using quantification algorithms with transcriptome alignment. If only genome 
alignment is possible and external GTF information is available, incorporating GTF 
information will yield higher performance.  
2.4.3   Impact of Expression Normalization Choice on Feature Quality 
2.4.3.1   Background 
RNA-seq for quantifying gene or transcript expression, one of the major 
applications of the NGS technology, has received increased attention because of its 
potential to replace the microarray technology. Some of the perceived benefits of RNA-
seq over microarrays include (1) improved dynamic range of expression detection and (2) 
the ability to detect a wide variety of RNA forms (e.g., small RNAs and splice variants) 
[32, 135]. Analogous to microarrays, normalization of RNA-seq data to obtain 
quantitative and comparable gene or transcript expression values is an important step [91, 
143, 144]. Several experimental factors in the sequencing process such as library 
preparation, sequencing depths, and base calling methods can introduce biases in 
downstream RNA-seq analysis. The purpose of the normalization step is to detect and 
adjust such biases. However, it is unclear how existing RNA-seq normalization methods 
handle various gene expression distributions. Using a simulated dataset, I compared 
several existing methods for RNA-seq expression normalization and evaluated them in 
terms of the recovery of designed fold changes. 
Most RNA-seq expression normalization methods are simple global normalization 
techniques that use a constant scaling factor for each sequencing sample. In this case 
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study, I investigated four existing RNA-seq normalization methods, including RPM / 
FPM [90], TMM [97], RLE [98], and Upper Quartile [96]. RPM / FPM adjust the total 
number of mapped reads per sample. However, RPM / FPM can be biased by relatively 
small proportions of highly-expressed genes and, as such, can bias DEG detection [96]. 
The number of reads expected to map to a gene is not only dependent on the expression 
level and the length of the gene, but also on the composition of the sampled RNA 
population. Normalization procedures such as TMM, RLE, and Upper Quartile attempt to 
estimate scaling factors between two samples to adjust total RNA output [97]. The TMM 
method trims log-ratio (M values) and log-average (A values) to find possible sets of 
stably expressed genes to estimate scaling factors. The RLE method generates a reference 
library by calculating the geometric mean of each gene across all samples, and the 
median ratio of each sample to the reference is taken as the scaling factor. The Upper 
Quartile method uses the ratio of the upper quartile between two samples as the scaling 
factor. The TMM, RLE, and Upper Quartile normalization also belong to global 
normalization methods. The difference between these methods and RPM / FPM is that 
they consider adjusting the total RNA output rather than the library size, which can 
reduce biases caused by highly-expressed genes. 
2.4.3.2   Datasets 
I assessed the robustness of normalization methods to various fold-change 
distributions using a simulated RNA-seq dataset. Table 11 summarizes five simulated 
gene expression distributions. I directly simulated raw counts of gene expression so as to 
eliminate possible errors introduced from the sequencing and sequence mapping steps. 
Using this dataset, I aim to investigate pros and cons of each normalization method.  
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Randomly select 5% of the 200 genes in “Simulated-Ground Truth” 
and increase their expression by 10-fold 
Simulated—Variant 2 
(Data Var2) 
Randomly select 20% of the 200 genes in “Simulated-Ground Truth” 
and increase their expression by 3-fold; and then randomly select 
another non-overlapping 20% of the 200 genes and decrease their 
expression by 3-fold 
Simulated—Variant 3 
(Data Var3) 
Uniform expression for all the 200 genes with gene expression equals 
to the median expression in “Simulated-Ground Truth” 
Simulated—Variant 4 
(Data Var4) 
70% lowest expressing genes in “Simulated-Ground Truth” are set to 




2.4.3.3   Results and Discussion 
In Figure 22, panel (a), I computed fold changes between Data Var1 and Data T 
and expected a fold change of 10 for 10 genes. RLE, TMM, and Upper Quartile methods 
were able to recover fold changes with less than 10% errors, but RPM was not. In Figure 
22, panel (b), I computed fold changes between Data Var2 and Data T. In this case, RLE 
and TMM were able to recover fold changes with less than 10% errors, whereas RPM 
and Upper Quartile were not. Figure 22, panel (c) shows results for an extreme, 
unrealistic case, that is, gene expression is uniformly distributed (Data Var3). TMM was 
the only method that correctly recovered fold changes with less than 10% errors. Figure 
22, panel (d) demonstrates results for another less realistic case in which the data contains 
excessive zero-expressing genes (Data Var4). RPM and TMM failed in this case. 
These results suggested that TMM and RLE methods are more robust expression 
normalization methods because they were capable of recovering fold changes within the 
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10% error margin for various simulated fold-change distributions. The RPM and Upper 
Quartile methods were susceptible to fold-change distributions with either a few highly-
expressed genes or many differentially expressed genes. 
 
 
Figure 22:  Recovered Fold Changes for Various Simulated Distributions. Panels (a) 
– (d) demonstrate the performance of several RNA-seq normalization methods for 
various simulated fold-change distributions. Each panel consists of five plots. From left 
to right, they are ground-truth fold changes, fold changes derived from RLE-normalized 





2.4.3.4   Summary of Case Study 
In this case study, I explored some existing RNA-seq normalization methods, 
including RPM, TMM, RLE, and Upper Quartile, and assessed their capability of 
tolerating different RNA-seq DEG distributions. Using simulated RNA-seq fold-change 
distributions, I observed that TMM and RLE failed only in one of the extreme scenarios. 
Upper Quartile and RPM were both sensitive to the distribution of fold changes. Thus, 
fold-change (or DEG) distribution is an important factor when choosing a normalization 
method for RNA-seq expression analysis. 
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2.4.4   Impact of Pipeline Choice on Feature Quality 
2.4.4.1   Background 
The first phase of the FDA-led microarray quality control project (MAQC-I) 
investigated and compared different genomic microarray technologies for quality 
verification [145]. The second phase of the project, MAQC-II, studied 30,000+ 
microarray gene expression-based data analysis pipelines to assess their prediction 
reproducibility for regulatory purposes [146]. Based on MAQC-I and MAQC-II, the FDA 
initiated MAQC-III (also known as sequencing quality control [SEQC]), which was an 
in-depth assessment of RNA-seq [32, 90, 135, 147]. Specifically, the goal of SEQC was 
to conduct a comprehensive evaluation of both RNA-seq technology and RNA-seq data 
analysis pipelines (i.e., RNA-seq pipelines), which was similar to the MAQC-I and 
MAQC-II evaluation of microarrays, as part of the FDA Critical Path Initiative 
(http://www.fda.gov/oc/initiatives/criticalpath/). While Su et al. summarized the SEQC 
RNA-seq technology investigation [148], this complementary case study summarizes the 
RNA-seq pipeline investigation. In particular, this case study examines the effect of 
RNA-seq pipelines on gene expression accuracy, precision, reliability, and 
reproducibility (defined in Section 2.3). 
For biological and medical applications, choosing a proper pipeline for RNA-seq 
gene expression remains a critical challenge due to its relative immaturity (i.e., fewer 
standards reported compared to microarrays), complexity, and diverse applicability. We 
performed a literature survey on RNA-seq pipelines consisting of sequence mapping [38, 
39, 73, 75, 82, 84, 85, 128, 129, 131], expression quantification [44, 46, 47, 72], and 
expression normalization [90, 97-99]. Multiple comparative investigations exist for 
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individual components of RNA-seq pipelines—mapping [128, 149-152], quantification 
[46, 95, 153, 154], and normalization [99, 155, 156]. However, despite the 
interdependence of these components [72], their joint impact is seldom comprehensively 
investigated. A previous investigation of 50 RNA-seq pipelines examined combinations 
of ten mapping and five quantification algorithms, but did not consider the interactive 
effects of different normalization algorithms [113]. Another study investigated three 
mapping, two quantification, and five DEG detection methods to assess concordance of 
gene expression and DEGs, but did not report on effects of interactions among pipeline 
components [112]. Both of these studies did not consider the effect of pipeline choice on 
downstream applications such as gene expression-based prediction. To the best of our 
knowledge, no studies have reported the joint effects of all components in RNA-seq 
pipelines and no guidelines exist for selecting RNA-seq pipelines for downstream 
prediction of disease outcome.  
The FDA first coordinated multiple sites of SEQC to generate a multi-replicate 
benchmark dataset (referred to as SEQC-Benchmark in this case study) [148], and then 
provided the dataset to our team to investigate the joint impact of pipeline components on 
gene expression estimation. Our team developed evaluation metrics (i.e., accuracy, 
precision, reproducibility, and reliability) for assessing a representative set of 278 RNA-
seq pipelines using the SEQC-benchmark dataset. 
2.4.4.2   Experimental Design 
We systematically investigated 278 RNA-seq pipelines (Table 12) that included 
combinations of 13 sequence mapping algorithms (Table 6) [38, 39, 73, 75, 82-84, 128, 
129, 131], three categories of expression quantification algorithms (Table 7) [44, 46, 47], 
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and seven expression normalization methods (Table 8). Sequence mapping algorithms 
were further categorized based on mapping strategy and mapping reporting. Mapping 
strategy refers to spliced or un-spliced algorithms. Un-spliced algorithms map whole read 
sequences while spliced algorithms split reads into smaller segments in order to 
accommodate long gaps such as introns. Mapping reporting refers to the number of 
mapping locations reported per read, either single-hit (i.e., one location reported per read) 
or multi-hit (i.e., multiple locations reported per read). To gain insight into these 
pipelines, we used the multi-site and multi-replicate SEQC-benchmark dataset along with 
a ground-truth quantitative PCR (qPCR) dataset. Table 13 and Table 14 summarize the 
SEQC-benchmark datasets and samples. Although qPCR can be variable and 
significantly different among platforms [148], we used it as a benchmark reference only 
after filtering the qPCR data based on the embedded ground-truth (Figure 52). The 
filtering process is detailed in the Appendix B section “Filtering the qPCR Benchmark 
Dataset to Produce a Reference Set of Genes.”  
 
Table 12:  RNA-seq Pipelines Investigated in Case Study 4. 
 
RNA-seq Pipeline Factors 





Bowtie, Bowtie2, BWA, GSNAP, Magic, 
MapSplice, Novoalign, OSA, RUM, 
STAR, Subread, TopHat, WHAM 
Strategy 2 Un-Spliced, Spliced 
Reporting 2 Single-Hit, Multi-Hit 
Quantification 
 




FPM, FPKM, Median, Upper Quartile, 
RLE, TMM, Magic Expression Index 
Total Pipelines 278*  





















and Mayo Clinic 
(MAY) 
A, B, C, D 4 
Each sample replicate was 
sequenced in 16 lanes across two 
flow cells, but we used data from 
only two lanes of a single flow 
cell for this study. 
Bio-Rad 
PrimePCR 




Table 14:  SEQC Benchmark Samples. 
 
Sample Name Sample Description 
A Stratagene’s Universal Human Reference RNA (UHRR) 
B Ambion’s Human Brain Reference RNA (HBRR) 
C A mixture of 75% A and 25% B 




As summarized in Table 12, the 13 mapping algorithms tested are Bowtie [73], 
Bowtie2 [75], BWA [38], GSNAP [82], Magic (a new pipeline developed by NCBI for 
the SEQC project) [121, 130], MapSplice [84], Novoalign (a commercialized package 
developed by Novocraft) [76], OSA [85], RUM [128], STAR [39], Subread [131], 
TopHat [83], and WHAM [129]. Some use un-spliced mapping of reads to the 
transcriptome, some others perform spliced mapping to the genome. The Magic pipeline 
uses both in parallel and compares the quality of each alignment to keep the best across 
multiple targets. Mapping algorithms may report only unique mapping, or allow for 
multiple mapping locations per read. Quantification algorithms include simple count-
based methods (i.e., HTSeq [44]) and Poisson model-based probabilistic methods applied 
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to either genomic (i.e., Cufflinks [47]) or transcriptomic mapping data (i.e., RSEM [46]). 
The Magic, RUM, and Subread (i.e., featureCounts [132]) pipelines  include embedded 
quantification methods that fall into the category of simple count-based methods. 
Normalization methods include simpler scaling methods (i.e., fragments per million 
mapped fragments [FPM], fragments per kilobase per million mapped fragments 
[FPKM], median, and upper quartile), more robust scaling methods (i.e., relative log 
expression [RLE] and trimmed mean of m-values [TMM]), and methods embedded in 
specific pipelines (i.e., Magic expression index). 
2.4.4.3   Datasets 
The FDA SEQC-benchmark dataset (Gene Expression Omnibus accession 
number GSE47792) includes paired-end RNA-seq data generated using the Illumina 
HiSeq 2000 platform with the read length of 100 bp [148]. We used a subset of the 
SEQC-benchmark dataset sequenced at two sites:  Beijing Genomics Institute (BGI) and 
Mayo Clinic (MAY). We used four samples (i.e., A, B, C, and D), each with four 
replicate libraries prepared at the sequencing sites. Sample A contains the Universal 
Human Reference RNA (UHRR), sample B contains the Human Brain Reference RNA 
(HBRR), sample C contains a mixture of A and B (75% A and 25% B), and sample D 
contains a mixture of A and B (25% A and 75% B). We used data from two lanes of a 
single flow cell for each sample replicate. The SEQC also provided the benchmark qPCR 
dataset that includes 20,801 genes assayed with PrimePCR (Bio-Rad, Hercules, 
California). Each PrimePCR gene was assayed once for each of the four samples (i.e., A, 
B, C, and D). The FDA SEQC benchmark datasets and samples are summarized in Table 
13 and Table 14. 
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2.4.4.4   Results and Discussion 
We systematically investigated 278 RNA-seq pipelines (Table 12) that included 
combinations of mapping, quantification, and normalization components listed in Table 
6, Table 7, and Table 8. To gain insight into these pipelines, we used the multi-site and 
multi-replicate SEQC-benchmark dataset and the qPCR benchmark dataset. Table 13 and 
Table 14 summarize SEQC benchmark samples and datasets. Table 15 summarizes the 
four benchmark metrics, including accuracy, precision, reliability, and reproducibility, 
used to evaluate pipelines. Details of these metrics have been discussed in Section 2.3.2. 
 
 
Table 15:  RNA-seq Pipeline Metrics for Case Study 4. 
 
Metric Description 





Accuracy is defined as the deviation of 
RNA-seq pipeline-derived log ratios from 
the corresponding qPCR-based log ratios.  
10,222 or 2,044 
Median 
Precision 
Precision is defined as the coefficient of 
variation over sample replicate libraries 
40,888 or 8,176 
(10,222 or 2,044 
genes × 4 
samples) 
Reliability 
Reliability is defined as the intraclass (or 
intra-sample in our case) correlation that 
quantifies how similar replicate libraries of 
a sample are to one another using ANOVA 
techniques 
10,222 or 2,044 
Reproducibility 
Reproducibility is defined as the Spearman 
correlation between two replicate libraries 
of the same sample. 
24 (6 comparisons 
per sample × 4 
samples) 
*All metrics are computed based on either 10,222 genes (denoted as “All Genes”) or 2,044 genes (denoted 






Impact of mapping, quantification, and normalization on gene expression accuracy 
We defined the accuracy metric as the deviation of RNA-seq pipeline-derived log 
ratios of gene expression from the corresponding qPCR-based log ratios, and visualized 
the median accuracy of all genes and low-expressing genes (refer to the Appendix B, 
Section “Filtering the qPCR Benchmark Dataset to Produce a Reference Set of Genes” 




Figure 23:  Median Accuracy of All and Low-Expressing Genes. The 278 RNA-seq 
pipelines applied to the SEQC-benchmark dataset differ in terms of the median accuracy 
of (a) all genes and (b) low-expressing genes. Accuracy is defined as the deviation of 
pipeline-derived log ratios from the corresponding qPCR-based log ratios. It is encoded 
as color, with red representing the highest accuracy, or the lowest deviation from qPCR. 
“All Genes” refers to the 10,222 qPCR genes after filtering, and “Low-Expressing 








Figure 23 continued. 
 
 
We observed the following results: 
(1) Using all genes, the median log-ratio deviation between RNA-seq and qPCR 
ranged from 0.27 to 0.63 (Figure 23, panel a). Smaller deviation represents 
higher accuracy. Median normalization exhibited the lowest deviation, or the 
highest accuracy, compared with all other normalization methods. In 
addition, Cufflinks and RSEM performed similarly despite the choice of 
mapping algorithms. Moreover, for all mapping-quantification combinations, 
the [Bowtie2 multi-hit + count-based] pipelines showed the largest deviation. 
Furthermore, pipelines with multi-hit mapping and count-based 
quantification generally showed larger deviation than other pipelines. Among 
all pipeline factors, normalization was the largest statistically significant 
(p<0.05) source of variation (Figure 24, panel a). 
b 
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(2) The median log-ratio deviation using low-expressing genes was larger than 
that using all genes, and it ranged from 0.45 to 0.69 (Figure 23, panel b). The 
trends of pipeline performance were similar to those using all genes, and 
normalization was also the largest statistically significant (p<0.05) source of 
variation (Figure 24, panel bError! Reference source not found.). 
(3) In summary, median normalization with most mapping and quantification 
algorithms, besides [Bowtie2 multi-hit + count-based], was the best choice 
for quantifying genes with high accuracy, or low deviation from qPCR.  
 These results suggested that mapping, quantification, and normalization methods 

















Figure 24:  ANOVA for Median Accuracy of All and Low-Expressing Genes. 
Analysis of variance (ANOVA) decomposes the overall variance in the median accuracy 
of (a) all genes and (b) low-expressing genes into various factors considered, including 
RNA-seq pipeline components and associated two-way interactions. The statistical 
significance of the contribution of each component and interaction is denoted by red 
asterisks, with ‘***’ indicates p-values are smaller than 0.001, ‘**’ indicates p-values are 
smaller than 0.01, and ‘*’ indicates p-values are smaller than 0.05. Among all factors, the 
normalization contributes the most to the overall variance. 
 
a Median Accuracy 
 (All Genes) 




Impact of mapping, quantification, and normalization on gene expression precision 
We defined the precision metric as the coefficient of variation (CoV) of gene 
expression across replicate libraries, and visualized the median precision of all genes and 





Figure 25:  Median Precision of All and Low-Expressing Genes. The 278 RNA-seq 
pipelines applied to the SEQC-benchmark dataset differ in terms of the median precision 
of (a) all genes and (b) low-expressing genes. Precision is defined as the coefficient of 
variation over replicate libraries. It is encoded as color, with red representing the highest 










Figure 25 continued. 
 
We observed the following results: 
(1) Using all genes, the median CoV ranged from 6.30% to 7.96% (Figure 25, 
panel a). Smaller CoV represents higher precision. Pipelines with any of 
Novoalign, GSNAP un-spliced, or WHAM mapping, and RSEM 
quantification resulted in higher CoV, despite the choice of normalization 
methods. In addition, the [Bowtie2 multi-hit + count-based + med.] pipeline 
always led to the largest CoV. Moreover, for each mapping-normalization 
combination, pipelines with either count-based or Cufflinks quantification 
always reported higher precision than those with RSEM quantification, 
except the [Bowtie2 multi-hit + count-based + med.] pipeline. Quantification, 
mapping algorithm, and their interaction were the largest statistically 
significant (p<0.05) source of variation (Figure 26, panel a). 
b 
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(2) The median CoV using low-expressing genes was larger than that using all 
genes, and it ranged from 11.0% to 15.5% (Figure 25, panel bError! 
Reference source not found.). The trends of pipeline performance were 
similar to those using all genes, except that the [Bowtie2 multi-hit + count-
based] pipelines exhibited the highest precision among others. Again, 
quantification, mapping algorithm, and their interaction were the largest 
statistically significant (p<0.05) source of variation (Figure 26, panel b). 
(3) In summary, pipelines with any of Bowtie2 multi-hit, GSNAP un-spliced, or 
Subread mapping and either count-based or Cufflinks quantification, besides 
the [Bowtie2 multi-hit + count-based + med.] pipeline, were the best choice 
for quantifying genes with high precision, or low CoV. 
These results suggested that mapping, quantification, and normalization methods 














Figure 26:  ANOVA for Median Precision of All and Low-Expressing Genes. 
Analysis of variance (ANOVA) decomposes the overall variance in the median precision 
of (a) all genes and (b) low-expressing genes into various factors considered, including 
RNA-seq pipeline components and associated two-way interactions. The statistical 
significance of the contribution of each component and interaction is denoted by red 
asterisks, with ‘***’ indicates p-values are smaller than 0.001, ‘**’ indicates p-values are 
smaller than 0.01, and ‘*’ indicates p-values are smaller than 0.05. Among all 
components and interactions, the quantification, mapping algorithm, and mapping 
algorithm-quantification interaction contribute the most to the overall variance. 
a Median Precision 
 (All Genes) 




Impact of mapping, quantification, and normalization on gene expression reliability 
We defined the reliability metric as the intraclass (i.e., intra-sample in the context 
of the SEQC-benchmark dataset) correlation (ICC) of gene expression, and visualized the 





Figure 27:  Median Reliability of All and Low-Expressing Genes. The 278 RNA-seq 
pipelines applied to the SEQC-benchmark dataset differ in terms of the median reliability 
of (a) all genes and (b) low-expressing genes. Reliability is defined as the intraclass (or 
intra-sample in our case) correlation that quantifies how similar replicate libraries of a 
sample are to one another using analysis of variance techniques. It is encoded as color, 









Figure 27 continued. 
 
 
We observed the following results: 
(1) Using all genes, the median ICC ranged from 0.972 to 0.991 (Figure 27, 
panel a). Larger ICC represents higher reliability. Median normalization 
exhibited the highest ICC, or the highest reliability, compared with all other 
normalization methods. In addition, pipelines with Novoalign mapping and 
RSEM quantification resulted in lower ICC despite the choice of 
normalization methods. Moreover, the [Bowtie2 multi-hit + count-based] 
pipelines showed the lowest ICC. Furthermore, for each mapping-
normalization combination, pipelines with either count-based or Cufflinks 
quantification always reported higher ICC than those with RSEM 
quantification, except the [Bowtie2 multi-hit + count-based] pipelines 
mentioned previously. Normalization was the largest statistically significant 
b 
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(p<0.05) source of variation, followed by two-way [mapping 
algorithm*quantification] interaction (Figure 28, panel a). 
(2) The median ICC using low-expressing genes was smaller than that using all 
genes, and it ranged from 0.938 to 0.975 (Figure 27, panel bError! Reference 
source not found.). The trends of pipeline performance were similar to those 
using all genes, except [Novoalign + RSEM] pipelines and [Bowtie2 multi-
hit + count-based] pipelines. Normalization, two-way [mapping 
algorithm*quantification] interaction, quantification, and mapping algorithm 
were the largest statistically significant (p<0.05) source of variation (Figure 
28, panel b). 
(3) In summary, median normalization along with most mapping and 
quantification algorithms, besides the [Bowtie2 multi-hit + count-based] and 
[Novoalign + RSEM] pipelines, was the best choice for quantifying genes 
with high reliability, or high ICC. 
These results suggested that mapping, quantification, and normalization methods 












Figure 28:  ANOVA for Median Reliability of All and Low-Expressing Genes. 
Analysis of variance (ANOVA) decomposes the overall variance in the median reliability 
of (a) all genes and (b) low-expressing genes into various factors considered, including 
RNA-seq pipeline components and associated two-way interactions. The statistical 
significance of the contribution of each component and interaction is denoted by red 
asterisks, with ‘***’ indicates p-values are smaller than 0.001, ‘**’ indicates p-values are 
a Median Reliability 
 (All Genes) 




smaller than 0.01, and ‘*’ indicates p-values are smaller than 0.05. Among all factors, the 
normalization contributes the most to the overall variance. 
 
Impact of mapping, quantification, and normalization on gene expression reproducibility  
We defined the reproducibility metric as the Spearman correlation between two 
replicate libraries of the same sample, and visualized the median reproducibility of all 





Figure 29:  Median Reproducibility of All and Low-Expressing Genes. The 278 
RNA-seq pipelines applied to the SEQC-benchmark dataset differ in terms of the median 
reproducibility of (a) all genes and (b) low-expressing genes. Reproducibility is defined 
as the Spearman correlation between two replicate libraries of the same sample. It is 











Figure 29 continued. 
 
 
We observed the following results: 
(1) Using all genes, the median Spearman correlation ranged from 0.993 to 0.996 
(Figure 29, panel a). Larger Spearman correlation represents higher 
reproducibility. Since the Spearman correlation is based on the rank values of 
gene expression, normalization methods scaling all expression with the same 
factor (i.e., all but the FPKM method) will lead to the same reproducibility 
values. The FPKM normalization method always exhibited the lower 
Spearman correlation, or the lower reproducibility, than the other 
normalization methods. In addition, pipelines with either Novoalign or 
GSNAP un-spliced mapping and RSEM quantification resulted in lower 
Spearman correlation despite the choice of normalization methods. 
b 
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Normalization, two-way [mapping algorithm*quantification] interaction, 
quantification, and mapping algorithm were the largest statistically 
significant (p<0.05) source of variation (Figure 30, panel a). 
(2) The median Spearman correlation using low-expressing genes was smaller 
than that using all genes, and it ranged from 0.962 to 0.987 (Figure 29, panel 
bError! Reference source not found.). The trends of pipeline performance 
were similar to those using all genes. Normalization, quantification, two-way 
[mapping algorithm*quantification] interaction, and mapping algorithm were 
the largest statistically significant (p<0.05) source of variation (Figure 30, 
panel b). 
(3) In summary, all but the FPKM normalization method with either Subread 
mapping and count-based quantification or GSNAP un-spliced mapping and 
Cufflinks quantification were the best choice for quantifying genes with high 
reproducibility, or high Spearman correlation. 
These results suggested that mapping, quantification, and normalization methods 













Figure 30:  ANOVA for Median Reproducibility of All and Low-Expressing Genes. 
Analysis of variance (ANOVA) decomposes the overall variance in the median 
reproducibility of (a) all genes and (b) low-expressing genes into various factors 
considered, including RNA-seq pipeline components and associated two-way 
interactions. The statistical significance of the contribution of each component and 
a Median Reproducibility 
 (All Genes) 




interaction is denoted by red asterisks, with ‘***’ indicates p-values are smaller than 
0.001, ‘**’ indicates p-values are smaller than 0.01, and ‘*’ indicates p-values are smaller 
than 0.05. Among all components and interactions, the normalization contributes the 
most to the overall variance. 
Investigating relationship between alignment profiles and benchmark metrics  
The performance of benchmark metrics depended on characteristics of mapping 
results. We used the M-estimation with Huber weighting to fit linear models that capture 
the relationship between the benchmark metrics and alignment profiles (see the Appendix 
B section “Regression Analysis” for details). The accuracy metric correlated with the 
number of mismatches per mapped read, and the precision, reliability, and reproducibility 
metrics correlated with the number of mapped fragments (Figure 31). Less mismatches 
per read and more mapped fragments led to more accurate, precise, reliable, and 
reproducibility gene expression. 
 
The Case Study 4 investigation using the SEQC-benchmark dataset demonstrated 
that gene expression estimation is significantly impacted by the joint effect of multiple 
















Figure 31:  Relationship between Alignment Profiles and Benchmark Metrics.  
Benchmark metric performance correlates with alignment profiles. For each panel, the x-
axis represents an alignment profile, and the y-axis corresponds to a benchmark metric. 
Each gray point represents a sequence mapping pipeline, and the blue line depicts the 
robust linear model using M-estimation with Huber weighting. Points in cyan have Huber 
weights less than 0.5 (i.e., potential outlying points). (a) The median deviation of all 
genes positively correlates with the number of mismatches per read. More mismatches 
per read results in higher deviation, or lower accuracy; (b) the median coefficient of 
variation (CoV) of all genes negatively correlates with the number of mapped fragments. 




intraclass correlation of all genes positively correlates with the number of mapped 
fragments. More mapped fragments results in higher intraclass correlation, or higher 
reliability; and finally (d) the median Spearman correlation of low-expressing genes 
positively correlates with the number of mapped fragments. More mapped fragments 
results in higher Spearman correlation, or higher reproducibility. 
 
2.4.4.5   Summary of Case Study 
We performed a systematic investigation of the 278 representative RNA-seq 
pipelines that resulted in multiple resources for RNA-seq users. In Case Study 4, after the 
SEQC conducted a broad investigation of RNA-seq technology [148], we developed a set 
of metrics to characterize RNA-seq pipelines using the SEQC-benchmark dataset. These 
metrics included the deviation of gene expression from qPCR data that quantifies 
accuracy; the CoV of gene expression across replicate libraries that quantifies precision; 
the ICC of gene expression grouped by samples that quantifies reliability; and the 
Spearman correlation between replicate libraries that quantifies reproducibility. We 
observed that RNA-seq pipeline components jointly affected gene expression estimation 
(Figure 23 to Figure 30). These joint effects had not previously been reported in studies 
that investigated individual RNA-seq pipeline components.  
We summarize and compare the results of our study to previous studies focusing 
on individual pipeline components. For example, previous studies observed that RUM, 
GSNAP spliced, STAR, and MapSplice mapping led to more accurate base-level 
alignment and splice junction detection [128, 150]. In addition, BWA, Bowtie, and 
Bowtie2 mapping were reported to be robust to sequencing errors and indels [149]. We 
similarly observed considerable differences in alignment profiles among mapping 
algorithms, and such the differences led to variations in the benchmark metrics (Figure 
31). For example, Bowtie2 multi-hit mapping aligned many more reads, a higher 
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percentage of which were sub-optimal mapping variants (i.e., secondary mappings, 
mismatches, insertions, deletions, and splicing), than WHAM single-hit mapping (Figure 
32, panels a – c). Consequently, pipelines with Bowtie2 multi-hit mapping resulted in 
larger deviation from the qPCR reference, or lower accuracy, than those with WHAM 
single-hit mapping. However, such the observation applied to only count-based 
quantification but not Cufflinks or RSEM (Figure 23). In addition to observations 
corresponding to previous literature, we also observed a joint effect between mapping 
and quantification components.  
Variations in mapping performance propagated to the quantification stage. 
Quantification strategy for multi-hit mappers may explain the variation in gene 
expression accuracy. For example, Cufflinks and RSEM use Poisson distribution-based 
models and assign probabilities to each mapping while HTSeq simply counts total 
mapped reads regardless of quality. Thus, Cufflinks and RSEM are better able to handle 
multi-hit information, resulting in smaller deviation from the qPCR reference (Figure 23 
and Figure 32, panel d). 
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Figure 32:  The Impact of Pipeline Choices on Mapping and Quantification 
Outcome. Bowtie2 multi-hit and WHAM single-hit pipelines differ significantly in terms 
of the percentage of total reported mappings for each mapping variant (i.e., secondary 
mapping, mapping with mismatches, insertion, deletion, and splicing). Each box 
demonstrates the distribution of percentages calculated from multiple sample replicates in 
the SEQC-benchmark dataset. The Bowtie2 multi-hit pipeline reports a higher percentage 
of mapping variants than the WHAM single-hit pipeline. (b) The WHAM single-hit 
pipeline reports only primary mappings. The box plot shows the distribution of the ratios 
of total primary or secondary mappings of the Bowtie2 multi-hit pipeline to total primary 
mappings of the WHAM single-hit pipeline using multiple sample replicates in the 
SEQC-benchmark dataset. The Bowtie2 multi-hit pipeline reports slightly more primary 
mappings than the WHAM single-hit pipeline, and it reports approximately five times 
more secondary mappings than the WHAM single-hit pipeline. These additional 
secondary mappings are informative for some expression quantification algorithms. (c) 
Gene body coverage differs between the Bowtie2 multi-hit and WHAM single-hit 
pipelines. The former pipeline reports additional secondary mappings between position 
3200 and 3800. (d) Gene body coverage adjusted by multi-hit assignment probabilities 
derived from the HTSeq or RSEM quantification pipeline. 
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2.5   Summary and Key Innovations 
In this chapter, I have addressed the first specific aim of this dissertation by 
designing several experiments (i.e., case studies) and evaluation metrics that can facilitate 
quality control of gene expression estimation. At the beginning of this chapter, I echoed 
Section 1.5 with the more specific introduction of RNA-seq feature extraction pipelines 
relevant to the four case studies described later in this chapter. Then, I detailed many 
evaluation metrics I designed for assessing the performance of these feature expression 
pipelines. Lastly, I elaborated on the experimental design, datasets, results, discussion, 
and conclusion of the four case studies.  
The first three case studies focused on investigating the effect of each individual 
pipeline component, including the genome annotation for sequence mapping, the 
quantification pipeline, and the normalization method. Figure 33 summarizes 
recommended RNA-seq pipeline components based on practical objectives. In contrast, 
the last case study (i.e., Case Study 4) emphasized on the joint effect of pipeline 
components on gene expression quality. The experimental design of this case study was 
much more complicated than the other three, and Figure 34 summarizes good-
performing RNA-seq pipelines for various RNA-seq applications.  
 
 
Figure 33:  Summary of Component-wise Investigation and Recommendation. 
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Figure 34:  Summary of Pipeline-wise Investigation and Recommendation. The 
resources provided by this study (i.e., the 278 RNA-seq pipelines, the benchmark metrics, 
and the SEQC-benchmark datasets) can serve as guidelines for biological and clinical 
researchers as well as for bioinformaticians and biotechnologists. Depending on the gene 
expression application, the accuracy, precision, reliability, and reproducibility metrics 
may be used to choose a pipeline. We have associated each metric with an RNA-seq 
application and listed the top-performing pipelines for each metric. The red-highlighted 
component in each listed RNA-seq pipeline indicates components that occur frequently 




The key innovations of the work in this chapter are listed as follows: 
 I designed a comprehensive list of evaluation metrics that capture the 
performance of RNA-seq expression analysis pipeline. 
 I conducted the first investigation on genome annotation and proposed a 
novel, informative annotation complexity measure. 
 I performed quantification pipeline investigation (among the first batch) and 
identified key factors for achieving accurate expression estimates. 
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 I accomplished the simulation-based investigation on expression 
normalization (among the first batch). 
 I performed the largest investigation of RNA-seq expression analysis pipeline 
so far using well-designed benchmark datasets provided by FDA. 
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CHAPTER 3    
KNOWLEDGE DISCOVERY FOR PRECISION MEDICINE 
 
3.1   Introduction 
As discussed in Chapter 1, this dissertation aims to promote precision medicine 
by addressing major challenges in the three directions—quality control, knowledge 
discovery, and integrative analysis. Challenges associated with quality control of gene 
expression estimation have been addressed in Chapter 2. With good gene expression 
quality, more reliable knowledge can be discovered. The second specific aim of this 
dissertation was to discover impactful biomarkers that can facilitate subgroup assignment 
using NGS data. This aim can be addressed from two perspectives—model construction, 
which establishes models that can ultimately classify patients into disease subgroups, and 
biomarker identification and interpretation, which reports statistically significant or 
predictive biomarkers that may be applicable in clinical settings. 
In this chapter, I first introduce methods for biomarker identification and 
predictive modeling specifically tailored to NGS data. Next, I use two case studies to 
demonstrate these methods and discuss findings from the two case studies. The 
background, experimental design, datasets, and results of the first case study are 
discussed based on its original publication [157], and those of the second case study are 




3.2   Biomarker Identification and Predictive Modeling for NGS Data 
After feature extraction, raw RNA-seq data can be represented as gene expression 
tables with typically tens of thousands of gene expression for tens or hundreds of 
samples. Knowledge discovery for RNA-seq gene expression tables can be two-fold—
identifying statistically significant biomarkers using statistical approaches or constructing 
predictive models using classification (a.k.a. supervised learning) techniques, both 
require predefined labels (i.e., known clinical outcome) for each sample in the study. In 
this section, I cover both perspectives. For the statistical modeling part, I first introduce 
how DEG detection works, followed by methods for protein DNA-binding site 
identification using chromatin immunoprecipitation sequencing (ChIP-seq) data. For the 
supervised learning part, I introduce a nested cross-validation technique I applied to 
estimate the prediction performance of clinical endpoints of interest. 
3.2.1   Differentially Expressed Gene Detection 
One most popular application of RNA-seq is to detect DEGs between two or more 
groups of samples. RNA-seq expression estimates from the two or more groups are first 
fit to a statistical distribution, followed by a statistical hypothesis test that determines 
whether the distributions between (among) the two or more groups are statistically 
significantly different for a targeted gene. Soneson et al. and Rapaport et al. have 
comprehensively conducted quantitative evaluation for DEG detection methods [158, 
159]. Thus, this section will mainly focus on qualitative categorization. 
DEG detection methods can be nonparametric or parametric. Nonparametric 
methods such as SAMseq [160] and NOISeq [161] use resampling and counting 
techniques to avoid making assumptions about the underlying distribution of RNA-seq 
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expression estimates. Data permutation is a common technique for estimating false 
discovery rates for nonparametric methods.  
Parametric methods use Poisson-based models to fit RNA-seq read count data 
[162]. The Poisson distribution has the variance equals to the mean. However, 
overdispersion (i.e., when the variance is significantly greater than the mean) often 
occurs in RNA-seq data. Therefore, the negative binomial distribution, which is a two-
parameter extension of the Poisson distribution, introduces an additional parameter to 
capture the high variability [98]. Selecting an appropriate statistical model is the key for a 
parametric DEG detection method. For example, DEGseq [163] applies the Poisson 
distribution to model RNA-seq read count data; edgeR [65], baySeq [164], and DESeq 
[98] use the negative binomial model to capture the overdispersion; Myrna [165] models 
the data as either the Gaussian distribution or the Poisson distribution; and Cuffdiff2 
[166] uses the beta negative binomial model to capture both overdispersion and 
uncertainty in the fragment count of a transcript. After constructing the statistical model, 
most parametric methods assess the significance level of each gene by using either p-
values computed from the likelihood ratio test or the Fisher’s exact test, or posterior 
probabilities estimated from the empirical Bayes method, while Cuffdiff2 assumes that 
RNA-seq data is normally distributed after a particular transformation and uses the t-test 
to determine the statistical significance of each DEG. 
3.2.2   Protein DNA-Binding Site Identification 
The bioinformatics pipeline for protein DNA-binding site identification using 
ChIP-seq data is composed of two steps—sequence mapping, which is very similar to 
that for RNA-seq data, and peak calling, which determine statistically significant peaks in 
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a dataset. Sequence reads generated from ChIP-seq mostly originate from DNA 
sequences around targeted protein DNA-binding regions. After mapping reads to the 
reference genome and identifying uniquely mapped reads, genomic loci that accumulate a 
large number of reads (i.e., peaks) indicate putative protein DNA-binding regions. Peak-
calling tools distinguish true peaks from background noise by (1) generating a signal 
profile along each chromosome, (2) defining a background noise model, (3) identifying 
candidate peak locations, and (4) assessing the significance of each candidate peak [36]. 
Peak-calling tools in earlier time quantify fold enrichment between samples of interest 
and expected background, and then apply the Poisson model to assess the significance of 
the enriched regions [36]. Recently developed peak-calling tools use the strand-
dependent bimodality information and adopt a more realistic background model to 
capture local variations [167]. 
3.2.3   Gene Expression-based Predictive Modeling 
Other than DEG detection, building prediction models using gene expression is 
also a popular RNA-seq application. Gene expression-based predictive modeling involves 
training classification models using gene expression tables with known clinical outcome 
as labels. Such the models can be used for future outcome prediction for any newly 
collected gene expression profiles. To assess prediction performance of certain clinical 
endpoints of interest without overfitting, the nested cross-validation technique is very 
popular that involves training and testing of an optimal prediction model. This is 
accomplished using the k-fold optimizing or inner cross-validation, applied to the training 
subset from the m-fold outer cross-validation. Once the final optimal prediction model 
parameters (i.e., the classifier hyperparameters and feature size) are identified, the final 
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model is trained using the entire training subset, and then tested using the remaining fold 
from the m-fold outer cross-validation. This process was repeated for several iterations to 
improve the robustness of prediction performance estimation. The nested cross-validation 
can be used with any kind of classifiers, such as adaptive boosting (AdaBoost), k-nearest 
neighbors (KNN), logistic regression (LR), random forests (RF), and support vector 
machines (SVM). In addition, since the number of genes (i.e., the number of features) is 
much larger than the number of samples, feature selection is necessary to reduce the 
dimensionality of the feature space. For gene expression data, the minimum redundancy, 
maximum relevance (mRMR) feature selection method is a popular method [168]. 
3.3   Case Study 
To demonstrate my proposed approach for knowledge discovery using RNA-seq 
or ChIP-seq data for precision medicine, I detail two case studies in this section, 
including biomarker identification for cardiovascular diseases and predictive modeling 
for cancers. The background, experimental design, datasets, and results of the first case 
study (i.e., biomarker identification for cardiovascular diseases) are discussed based on 
its original publication [157], and those of the second case study (i.e., predictive 
modeling for cancers) are in preparation for submission to Nature Methods. 
3.3.1   Biomarker Identification for Cardiovascular Diseases 
3.3.1.1   Background 
Cardiovascular disease (CVD) is the leading cause of death worldwide. Prediction 
and prevention of CVD, such as coronary artery disease and atherosclerosis, traditionally 
depend on identification of risk factors [169, 170]. These factors are effective in the 
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general assessment of CVD risk, but are not consistent indicators for all individuals 
[171]. Therefore, CVD research has recently been expanded to include the identification 
of -omic biomarkers (e.g., genomic, transcriptomic, and epigenomic) that may (1) 
improve the understanding of the molecular mechanisms of CVD, (2) facilitate the 
development of personalized CVD care, and (3) reduce CVD mortality rates by 
accurately identifying high-risk individuals [172]. NGS is a promising technology to 
identify -omic biomarkers. Because of its high-throughput capability in discovering novel 
genomic features with base-pair resolution, NGS is projected to play an increasingly 
important role in clinical diagnostics and personalized medicine for CVD [173, 174]. 
NGS and associated bioinformatics methods have been applied to cardiovascular 
genomics, transcriptomics, and epigenomics. Figure 35 illustrates four NGS applications 
such as (A) identification of DEGs using RNA-seq, (B) identification of protein-binding 
regions in the genome using ChIP-seq, (C) identification of genetic variants in exon 
regions using exome sequencing, and (D) identification of genomic methylation patterns 
using methyl-CpG-binding domain sequencing (MBD-seq). These applications identify 
and quantify -omic biomarkers that may be clinically viable for early disease diagnosis 
and effective disease treatment and management. In this case study, I focus on two major 
applications of NGS technology:  (1) RNA-seq, which has enabled researchers to 
characterize CVD by studying transcriptome-wide expression profiles [175], alternative 
splicing patterns [176], and miRNA regulatory networks [177]; and (2) ChIP-seq, which 
has enabled researchers to examine the epigenetic mechanisms of CVD by profiling the 
genome-wide pattern of protein-binding regions (e.g., transcription factors and 




Figure 35:  NGS Facilitates the Identification of -Omic Biomarkers for CVD. (A) 
RNA-seq detects differentially expressed genes by comparing gene expression profiles of 
CVD samples to those of control samples. (B) ChIP-seq identifies transcription factor 
activity by detecting peaks formed by mapping DNA sequence reads that bind to 
transcription factor proteins. Transcription factor activity correlates with gene expression. 
(C) Exome sequencing detects genetic variants such as SNPs that may correlate with 
CVD phenotypes. (D) MBD-seq is similar to ChIP-seq, but identifies regions of DNA 






I demonstrate the utility of NGS bioinformatics for cardiovascular research by 
applying RNA-seq and ChIP-seq pipelines to publicly available CVD RNA-seq and 
ChIP-seq datasets downloaded from the NCBI SRA repository. In each NGS application, 
I illustrate the NGS bioinformatics solution for CVD research; evaluate the performance 
of the critical step that identifies CVD biomarkers; and discuss the remaining 
bioinformatics challenges. 
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3.3.1.2   Experimental Design 
DEG Detection Using RNA-seq 
The bioinformatics pipeline for identifying DEGs using RNA-seq data includes 
sequence mapping, expression quantification, expression normalization, and DEG 
detection (Figure 36). I use the same sequence mapper TopHat [83]  and expression 
quantifier Cufflinks [47] with eight different DEG detection tools to construct eight 
pipelines. Each DEG detection tool implements an expression normalization method that 
optimizes its DEG detection performance. TopHat maps four RNA-seq samples (detailed 
in the Section 3.3.1.3 “Datasets”) to the GRCm38/mm10 mouse genome [180] with the 
guidance of the RefSeq genome annotation [125]. Cufflinks quantifies gene and transcript 
expression in terms of raw read counts. The eight DEG detection tools (Figure 36, left 
table) include both nonparametric (e.g., SAMseq [160] and NOISeq [161]) and 
parametric methods (e.g., baySeq [164], Cuffdiff2 [166], DESeq2 [98], DSS [181], 
edgeR [65], and Limma+Voom [182]) that represent a wide variety of prevalent and 
novel algorithms. The significant DEGs are identified with adjusted p-values less than 
0.05. To evaluate the performance of the eight pipelines, I have designed five metrics:  
(1) The authors of the original paper [183] performed qPCR validation for 16 cardiac 
hypertrophy- or fibrosis-related genes. Among 16 genes, only 12 were reported to 
be significantly differentially expressed. To assess the power of RNA-seq, I use 
the concordance of these 12 DEGs between qPCR and eight RNA-seq pipelines as 
the first metric. For genes detected by less than four out of the eight pipelines, I 




Figure 36:  Bioinformatics Pipelines for RNA-seq and ChIP-seq Data. Green arrows 
indicate the pipeline for RNA-seq data and blue arrows represent the pipeline for ChIP-
seq data. Selected DEG detection and peak-calling tools are listed following alphabetical 




(2) To assess the biological relevance of DEGs, I use the ToppFun web-based tool in 
the ToppGene Suite [184] to annotate the functions of DEGs in terms of 114 
significant Gene Ontology (GO) terms and four significant pathways with 
adjusted p-values less than 0.05. The GO terms and pathways associated with the 
16 cardiac hypertrophy- or fibrosis-related genes are defined as the ground-truth 
functional annotation (Figure 37, Panel B). I use the concordance between the 
pipeline-specific annotations and the ground-truth as the second metric. 
(3) To assess the reproducibility among various DEG detection tools, I compute the 
number of overlapping DEGs among the eight tools as the third metric. 
(4) To assess the expression profiles of DEGs, I used the ratio of the dominant read 
count (i.e., the largest read count of a DEG across all samples) to the total read 
count for any DEG g, and its distribution as the fourth metric: 
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𝑅𝑑𝑜𝑚𝑖𝑛𝑎𝑛𝑐𝑒,𝑔 =
𝑀𝑎𝑥(𝐴1,𝑔, 𝐴2,𝑔, 𝐵1,𝑔, 𝐵2,𝑔)
𝑆𝑢𝑚(𝐴1,𝑔, 𝐴2,𝑔, 𝐵1,𝑔, 𝐵2,𝑔)
. (19) 
A1,g, A2,g, B1,g, and B2,g are normalized read counts after adjusting the sequencing 
depth effect for samples A1, A2, B1, and B2 for any DEG g. [A1, A2] and [B1, B2] 
are biological replicates for the wild-type and Ezh2-deficient samples , 
respectively (detailed in the Section 3.3.1.3 “Datasets”). Given Equation (19), the 
range of Rdominance,g is from 25% (i.e., A1,g=A2,g=B1,g=B2,g) to 100% (i.e., 
Max=Sum) with a few possible scenarios:  (a) if a gene is not significantly 
differentially expressed and the variability between replicates is small, the 
normalized read counts A1,g, A2,g, B1,g, and B2,g will only differ slightly from one 
another, and the Rdominance,g will be close to 25%; (b) if a gene is highly 
differentially expressed and the variability between replicates is small, Rdominance,g 
will be around 50%; and (c) if the variability between replicates is large, 
Rdominance,g can be significantly greater than 50% (e.g., Rdominance,g= 80% if [A1,g, 
A2,g, B1,g, B2,g] = [120, 30, 0, 0]).  
(5) To assess the capability of each tool for detecting highly-expressed or low-
expressed DEGs, I calculate the mean read count of each DEG g from the 
normalized read counts (i.e., A1,g, A2,g, B1,g, and B2,g) as the fifth metric. 
Peak Calling Using ChIP-seq 
The bioinformatics pipeline for identifying genome-wide protein-binding regions 
using ChIP-seq includes sequence mapping and peak calling (Figure 36). I use the same 
sequence mapper, Bowtie, and six different peak-calling tools to construct totally six 
pipelines. Bowtie [73] maps sequence reads (or sequence “tags” in ChIP-seq) to the 
GRCh37 / hg19 human genome [185] and reports only uniquely mapped tags. The six 
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peak-calling tools (Figure 36, right table), including SISSRs [57], MACS [56], 
FindPeaks [186], SWEMBL [187], SICER [188], and F-Seq [189] represent a wide 
variety of algorithms for determining statistically significant peaks. I run these tools 
using their default or recommended parameters with a p-value threshold of 10
-3
. The 
identified peaks are putative protein-binding regions for p300 and CBP proteins (detailed 
in the Section 3.3.1.3 “Datasets”). 
To assess the performance of the six peak-calling tools, I have designed five 
metrics:  (1) to visualize sequence-mapping and peak-calling information using the 
Integrative Genomics Viewer [190]; (2) to count the total number of peaks called by each 
tool; (3) to investigate the distribution of Ni, the normalized tags per peak, as defined in 
the Equation (20): 
𝑁𝑖 =
(𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑇𝑎𝑔𝑠)𝑖
(𝑃𝑒𝑎𝑘 𝐿𝑒𝑛𝑔𝑡ℎ 100⁄ )𝑖
 ; (20) 









where N is the total number of peaks; and (5) to biologically validate the peaks by 
investigating the percentage of peaks that contain at least one p300 motif using the FIMO 
(find individual motif occurrences) program [191] with a p-value threshold of 10
-4
. The 
input information for the FIMO program includes DNA sequences corresponding to these 
peaks and the position-specific scoring matrix for the p300 motif retrieved from the 
SwissRegulon Portal [192]. 
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3.3.1.3   Datasets 
The RNA-seq dataset (SRA accession:  SRP009662) was acquired to investigate 
the effects of Ezh2 deletion on postnatal cardiac development, homeostasis, and gene 
expression [183]. The authors reported that the loss of Ezh2 gene in cardiac precursors 
would lead to cardiac hypertrophy and fibrosis. This dataset contains wild-type and Ezh2-
deficient adult mouse right ventricle samples, each with two biological replicates. Each 
sample was sequenced with the Illumina HiSeq 2000 platform and contains around 30 
million 2×50 bp read pairs. 
The ChIP-seq dataset (SRA accession:  SRP008658) investigated the genome-
wide map of human heart enhancers with a pan-specific antibody that targets two closely-
related transcriptional coactivator proteins, p300 and CBP (CREB-binding protein) [193]. 
This dataset contains tissue samples from one fetal and one adult human heart. Each 
sample was sequenced with Illumina Genome Analyzer and contains around 27 million 
36 bp single-ended reads. 
3.3.1.4   Results and Discussion 
DEG Detection Using RNA-seq 
I have evaluated the performance of the eight DEG detection tools by five metrics 
(Figure 37, Panels A-F). Using the 12 qPCR-validated DEGs, Panel A shows that 
nonparametric methods such as NOISeq and SAMseq, and parametric methods such as 
Cuffdiff2 and edgeR, were able to identify at least half of these 12 DEGs. In contrast, 
parametric methods, such as baySeq, DESeq2, DSS, and Limma+Voom, were able to 
identify only one or two of these 12 DEGs. Six genes were difficult to detect by RNA-
seq-based methods (marked in red). The expression pattern of these difficult genes shows 
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that they have either smaller fold changes (e.g., Tgfb3) or higher between-replicate 
variability (e.g., Actn3).  
Panel B listed the top 20 GO terms and all four pathways from the ground-truth 
functional annotations, most of which were linked to the mechanisms of muscle 
contraction and heart development. Panel C summarized the concordance between the 
pipeline-specific annotations and the ground-truth in terms of the top 20 GO terms 
(ranked by p-values), all GO terms, and all pathways. DEGs detected by baySeq, DSS, 
and Limma+Voom were associated with zero GO terms and only a few pathways, which 
suggested that these tools detected DEGs with very diverse functions. DEGs detected by 
edgeR and Cuffdiff2 had more high-rank functional annotations concordant with the 
ground-truth annotation. In contrast, DEGs detected by DESeq2, SAMseq, and NOISeq 
were linked to many GO terms and pathways that were biologically irrelevant to the 
original study, with no concordance appeared in the top 20 GO terms. 
Panel D showed the number of DEGs supported by one, two, or all eight tools for 
each DEG detection method. baySeq, DSS, and Limma+Voom identified a fewer number 
of DEGs (i.e., 32, 23, and 12, respectively) that were highly reproducible among various 
tools (i.e., each DEG were supported by at least two other tools). Tools with more 
detected DEGs, such as SAMseq, NOISeq, and DESeq2, tended to have more pipeline-
specific or unique DEGs. However, as discussed earlier, a higher number of DEGs did 
not necessarily lead to more biologically relevant results. Panel E demonstrated the 
distribution of Rdominance,g for DEGs. Most DEGs had Rdominance,g in the range of 25% to 
60% following the scenarios (4a) and (4b) I have discussed in Section 3.3.1.2 
“Experimental Design” for RNA-seq. Such observation indicated that most DEGs 
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detected by RNA-seq pipelines did not have huge variability between biological 
replicates. DEGs with larger between-replicate variability resulted in Rdominance,g greater 
than 60%. Such high variability can be the nature of biological replicates or biases 
introduced in the sequencing or analytical processes. The nonparametric NOISeq method 
had the highest percentage of DEGs with Rdominance,g greater than 60% since it identified 
many genes with very low read counts (e.g., [A1,g, A2,g, B1,g, B2,g]=[1, 1, 0, 0]). Thus, a 
small deviation in the read counts may have caused a huge variation in Rdominance,g. For 
parametric methods, higher Rdominance,g indicated that the read counts may not follow a 
negative binomial distribution [160]. edgeR and Cuffdiff2 had a higher chance of 
detecting this type of genes as DEGs. Panel F showed the distribution of the mean read 
counts of DEGs. NOISeq had a bimodal distribution because of its tendency to identify 
some DEGs with very low read counts. The other seven tools shared a similar range of 
the mean read counts of DEGs, with baySeq slightly skewed to the left (i.e., lower mean 




Figure 37:  Functional and Quantitative Assessment of DEG Detection Tools. (A) 
Checkmarks indicated concordant DEGs between qPCR validation conducted by the 
original study and the results from the eight DEG detection tools. Genes marked in red 
were identified by less than four out of the eight tools. (B) The top 20 significant GO 
terms and all four significant pathways of the ground truth functional annotation, which 
was established by annotating the 16 qPCR validated genes. (C) The number of 
concordant GO terms and pathways between ground-truth and pipeline-specific 
annotations. (D) The number of DEGs supported by one, two, or all eight tools for each 
DEG detection pipeline. (E) The distribution of the ratio of dominant read counts to total 
read counts of all DEGs for each DEG detection pipeline. (F) The distribution of the 




Peak Calling Using ChIP-seq 
I have investigated the performance of the six peak-calling tools by five metrics 
(Figure 38, Panels A-E). Visualizing by the Integrative Genomics Viewer, Panel A 
showed the peak regions called by the six tools with corresponding coverage information 
from the Bowtie alignment in the upstream region of the INPP5A gene (inositol 
polyphosphate-5-phsphatase, 40kDa). The selective nature of SISSRs and MACS 
resulted in sparse and short peaks. In contrast, FindPeaks and SWEMBL tended to call 
very long peaks with lengths over 10 kbp. Panel B demonstrated the number of peaks 
called by the six tools. SICER called the largest number of peaks, followed by FindPeaks 
and F-Seq. SICER failed to form longer peaks by merging nearby peaks, resulting in a 
relatively higher number of peaks. FindPeaks called two separate peaks even though two 
protein-binding regions were in close proximity; thus, FindPeaks also tended to call more 
peaks than the other tools. Panel C depicted the distribution of the number of tags per 
peak normalized by the peak length. Larger numbers indicated that the detected peaks 
were supported by more evidence. SISSRs, MACS, SWEMBL, and F-Seq exhibited a 
moderate to high number of tags per peak. In contrast, FindPeaks and SICER detected 
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some peaks with a very low number of tags per peak. These peaks may not have been 
reliable because of limited evidence. Panel D showed the average length of peaks called 
by the six tools. Among them, SWEMBL had the longest average length, which may not 
have been a reasonable length for protein DNA-binding sites. SISSRs, MACS, and F-Seq 
exhibited the average peak length of less than 400 bp, which was close to the designed 
fragment length from the Illumina sequencing protocol. 
Using the FIMO program, Panel E demonstrated the percentage of peaks that 
contained the p300 motif. MACS performed the best with 15% to 23% of the peaks 
containing the motif. SISSRs and F-Seq performed moderately well with their motif 
discovery rate ranging from 6% to 8%. Even though FindPeaks and SICER detected a 
significantly larger number of peaks than the others, only 2% to 3% of these peaks 
contained the p300 motif, exposing their relatively high false positive rates. Around 11% 
to 22% of peaks called by SWEMBL contained the p300 motif. However, despite such 
high performance, the peaks were not reliable since SWEMBL had extremely long peaks 
on average, which increased the probability of identifying the motif by chance alone.  
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Figure 38:  Qualitative and Quantitative Assessment of Various Peak-Calling Tools. 
(A) IGV visualized peaks called by the six tools in the upstream region of the INPP5A 
gene using the adult heart sample. The black histogram on the top represented the 
coverage of Bowtie alignment in the same region. (B) The number of peaks detected by 
each peak-calling pipeline. (C) The distribution of the number of tags per peak 
normalized by the peak length for each peak-calling pipeline. (D) The average length of 
peaks for each peak-calling pipeline. (E) The percentage of peaks that contains at least 
one p300 motif identified by the FIMO program with a p-value threshold of 10
-4




3.3.1.5   Summary of Case Study 
In summary, the original paper of the RNA-seq dataset studied the effect of Ezh2 
deletion on gene expression profiles. It identified a set of DEGs relevant to cardiac tissue 
development and remodeling [183]. My study examined the functions of DEGs detected 
by the eight RNA-seq pipelines, and edgeR and Cufflinks yielded the most functionally 
relevant DEGs. The nonparametric methods such as NOISeq and SAMseq identified 
many more DEGs than other tools, yet a large proportion of these DEGs may have been 
less reliable (e.g., DEGs with very low read counts) and irrelevant to the biology of the 
original study. RNA-seq technology provides an opportunity to comprehensively study 
the transcriptome. While fixing sequence mapping and expression quantification steps 
and focusing on evaluating only DEG detection methods, I found that different tools 
generated very different DEG sets. Therefore, translating the computational findings into 
real clinical applications requires integrative biological interpretation and large-scale 
experimental validation. In addition, RNA-seq technology can be unreliable for 
estimating expression of low-expressing genes, but currently no standardized methods are 
capable of handling them properly. Thus, distinguishing true signals from noise for low-
expressing genes remains a challenge. 
For the ChIP-seq dataset, the original study used ChIP-seq with the antibody that 
recognizes the enhancer-associated coactivator proteins p300 and CBP to annotate 
candidate heart enhancers that may regulate the expression of heart development-related 
genes in the human genome. By examining the percentage of peak regions (i.e., candidate 
heart enhancer regions) that contained the p300 motif, MACS achieved the highest motif 
discovery rate among the six tools, which suggested that MACS identified more 
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biologically relevant peaks than the others. In addition, MACS’s peaks had the second 
highest tag coverage and the reasonable average peak length. In contrast, SICER 
identified peaks with the lowest motif discovery rate and very low tag coverage. Most 
peak-calling tools need control samples for building background models essential for 
conducting statistical tests. These background models can be local or global. The global 
model is easier to build but lacks the consideration of local biases. Accurately identifying 
peaks requires an adaptive background signal model that can dynamically change 
parameters to accommodate local variations and different ChIP-seq experiments.  
3.3.2   Prediction Models for Cancers 
3.3.2.1   Background 
This case study is part of the SEQC project, and it is also the continuation of Case 
Study 4 in Chapter 2 (i.e., Section 2.4.4). Please refer to Section 2.4.4 for detailed 
information about the RNA-seq pipeline study focusing on benchmark datasets and 
associated benchmark metric performance. In contrast to Chapter 2, Case Study 4, this 
case study examines the effect of RNA-seq pipelines on downstream gene expression-
based prediction of disease outcome. Similar to Chapter 2, Case Study 4, we did a 
comprehensively literature survey about the effect of RNA-seq pipelines on downstream 
prediction performance. To the best of our knowledge, no studies have reported the effect 
of RNA-seq pipeline components on gene-expression-based prediction performance and 
no guidelines exist for selecting RNA-seq pipelines for prediction of disease outcome. 
The FDA coordinated with the BGI to generate a clinical dataset consisting of 
neuroblastoma patient samples (referred to as SEQC-neuroblastoma) [194], and then 
provided this datasets to SEQC teams to investigate the joint impact of pipeline 
 126 
components on downstream gene expression-based prediction. We quantified gene 
expression in the SEQC-neuroblastoma dataset and the lung adenocarcinoma dataset 
(referred to as TCGA-lung-adenocarcinoma) downloaded from The Cancer Genome 
Atlas (TCGA), and then determining if RNA-seq pipeline components contributed to 
variations in prediction performance of disease outcome. 
3.3.2.2   Experimental Design 
We used the SEQC-neuroblastoma and TCGA-lung-adenocarcinoma datasets to 
assess the effect of upstream RNA-seq pipeline components on downstream prediction of 
disease outcome. The total number of RNA-seq pipelines considered was 278, as 
summarized in Table 12. The SEQC-neuroblastoma dataset, provided by the SEQC 
consortium, contains RNA-seq data of 176 primary neuroblastomas obtained from high-
risk patients with well-annotated clinical data [194], in which survival information, 
including event-free survival (EFS) and overall survival (OS), was used for defining 
group labels for predictive modeling. The TCGA-lung-adenocarcinoma dataset contains 
RNA-seq data of patients with known survival time used for defining group labels.  
3.3.2.3   Datasets 
We used a 176-sample neuroblastoma dataset (a subset of a larger 498-sample 
dataset; accession GSE47792) to assess the performance of RNA-seq pipelines in terms 
of gene expression-based prediction of disease outcome. These samples were provided by 
the University Children’s Hospital of Cologne and sequenced at BGI using the Illumina 
platform [194]. All 176 samples were taken from high-risk patients that were defined as 
those either with stage 4 neuroblastoma and age >18 months or with MYCN-amplified 
tumors of any stage or age. 
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We predicted two clinical endpoints—event-free survival (EFS), that is, the 
occurrence of events such as progress, relapse, or death, and overall survival (OS), that is, 
death. For both endpoints, patients were partitioned into two groups (i.e., high risks 
versus long risks). High-risk patients experienced an event or died before a predefined 
survival-time threshold, while low-risk patients experienced an event or died after the 
threshold, or their last follow-up exceeded the threshold. Survival-time thresholds for 
EFS and OS were two and three years, respectively. The thresholds were chosen to 
balance the number of high-risk and low-risk patients. Details of the SEQC-
neuroblastoma dataset are provided in Table 16. 
 
 
Table 16:  Prediction Endpoints for the SEQC Neuroblastoma Dataset. 
 





[Threshold = 2 years] 
Event occurred after the threshold  
OR 
Patient’s last follow-up exceeded the threshold 
(no information about patient’s event occurrence 
after the last follow-up) 
67 
Event occurred before the threshold 97 
Overall Survival  
(OS) 
[Threshold = 3 years] 
Patient died after the threshold 
OR 
Patient’s last follow-up exceeded the threshold 
(no information about patient’s survival after the last 
follow-up) 
83 
Patient died before the threshold 70 
 
 
We also used an 87-sample lung adenocarcinoma RNA-seq dataset from The 
Cancer Genome Atlas (TCGA) repository. The prediction endpoint was also survival, and 
we used the same criteria to define high-risk and low-risk groups with the survival-time 
threshold of two years. The two-year threshold was chosen to balance the number of 
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high-risk and low-risk patients. Details of the TCGA-lung-adenocarcinoma dataset are 
provided in Table 17. 
 
 
Table 17:  Prediction Endpoint for the TCGA Lung Adenocarcinoma Dataset. 
 




[Threshold = 2 years] 
Patient died after the threshold 
OR 
Patient’s last follow-up exceeded the 
threshold 
(no information about patient’s survival after 
the last follow-up) 
47 




3.3.2.4   Results and Discussion 
We used the same set of 278 RNA-seq pipelines to process the SEQC-
neuroblastoma dataset (we used only 156 out of the 278 pipelines for the TCGA-lung-
adenocarcinoma dataset). For each set of estimated gene expression (278 sets for 
neuroblastoma and 156 sets for lung adenocarcinoma), we performed nested cross-
validation (Figure 39) using three classifiers—AdaBoost, LR, and SVM. For each 
clinical endpoint—neuroblastoma EFS, neuroblastoma OS, and lung adenocarcinoma 
survival—we calculated the AUC (area under the receiver operating characteristics 
curve) and MCC (Matthews correlation coefficient), and visualized these using heatmaps 









Figure 39:  Predictive Modeling Using the Nested Cross-Validation Technique. For 
the outer cross-validation, input data are randomly split into training and testing subsets 
(green boxes) following the standard 5-fold cross-validation protocol. For each of the five 
training subsets, the 3-fold optimizing or inner cross-validation (yellow boxes) is applied 
to optimize the feature size and hyperparameters for classifiers. The optimal feature size 
and hyperparameters (blue boxes) are used to train a final classifier (pink boxes) that will 
be directly applied to the testing subset. The final predictive modeling performance is 
measured by both the area under the receiver operating characteristic curve (AUROC, or 












Figure 40:  Prediction Performance of NB EFS Measured by AUC and MCC. The 
278 RNA-seq pipelines applied to the SEQC-neuroblastoma (NB) dataset differ in terms 
of prediction performance measured by (a) AUC and (b) MCC. The predictive modeling 
procedure is detailed in Figure 39, and the prediction endpoint is dichotomized event-
free survival (EFS) with the survival-time threshold of two years. Prediction performance 








Figure 41:  Prediction Performance of NB OS Measured by AUC and MCC. The 
278 RNA-seq pipelines applied to the SEQC-neuroblastoma (NB) dataset differ in terms 
of prediction performance measured by (a) AUC and (b) MCC. The predictive modeling 
procedure is detailed in Figure 39, and the prediction endpoint is dichotomized overall 
survival (OS) with the survival-time threshold of three years. Prediction performance is 








Figure 42:  Prediction Performance of LUAD Survival Measured by AUC and 
MCC. The 156 RNA-seq pipelines applied to the TCGA-lung-adenocarcinoma (LUAD) 
dataset differ in terms of prediction performance measured by (a) AUC and (b) MCC. 
The predictive modeling procedure is detailed in Figure 39, and the prediction endpoint 
is dichotomized survival with the survival threshold of two years. Prediction performance 





We observed the following results: 
(1) For the neuroblastoma EFS endpoint, pipelines using count-based 
quantification with TMM, RLE, upper quartile, or median normalization 
tended to achieve high AUC and MCC; while those with FPM or FPKM 
normalization tended to perform poorly. In addition, Novoalign with 
Cufflinks and Bowtie2 or BWA with RSEM led to poor AUC and MCC, 
especially when combining with FPM or FPKM normalization (Figure 40). 
(2) For the neuroblastoma OS endpoint, median normalization led to higher AUC 
and MCC than other normalization methods for most mapping-quantification 
combinations. GSNAP un-spliced mapping performed well with count-based 
or Cufflinks quantification but not RSEM quantification. In addition, 
pipelines with RSEM quantification and any of upper quartile, RLE, or TMM 
normalization tended to result in poor AUC and MCC (Figure 41). 
(3) For the lung adenocarcinoma survival endpoint, pipelines with count-based 
quantification and TMM normalization tended to achieve high AUC and 
MCC. TopHat alignment with either count-based or Cufflinks quantification 
also performed well. In contrast, pipelines with any of Novoalign single-hit, 
STAR, GSNAP un-spliced multi-hit, or Bowtie2 multi-hit and Cufflinks 
resulted in lower AUC and MCC (Figure 42). 
(4) ANOVA for each neuroblastoma endpoint showed that normalization was the 
largest statistically significant (p<0.05) source of variation, followed by 
mapping algorithm, two-way [mapping algorithm*quantification] interaction, 
and two-way [quantification*normalization] interaction (Figure 43 and 
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Figure 44). For the lung adenocarcinoma endpoint, several pipeline 
components and their interactions contributed more evenly to the overall 
variance that may be due to only 156 pipelines were conducted (Figure 45). 
All ANOVA reported large residual variance that should be explained by 
higher order interactions. 
Results suggested that the choice of upstream RNA-seq pipeline components 




















Figure 43:  ANOVA for Prediction Performance of NB EFS. Analysis of variance 
(ANOVA) decomposes the overall variance in prediction performance of NB EFS into 
various factors considered, including RNA-seq pipeline components and associated two-
way interactions. Panels (a) and (b) show the ANOVA for prediction AUC and MCC, 
respectively. Prediction performance of various classifiers has been averaged before 
applying the ANOVA. The statistical significance of the contribution of each component 
and interaction is denoted by red asterisks, with ‘***’ indicates p-values are smaller than 
0.001, ‘**’ indicates p-values are smaller than 0.01, and ‘*’ indicates p-values are smaller 
than 0.05. Among all components and interactions, the normalization contributes the 
most to the overall variance. Around a quarter of the overall variance belongs to residuals 
that cannot be explained by the factors considered. 
a Prediction 
Performance 
of NB EFS (AUC) 
b Prediction 
 Performance 




Figure 44:  ANOVA for Prediction Performance of NB OS. Analysis of variance 
(ANOVA) decomposes the overall variance in prediction performance of NB OS into 
various factors considered, including RNA-seq pipeline components and associated two-
way interactions. Panels (a) and (b) show the ANOVA for prediction AUC and MCC, 
respectively. Prediction performance of various classifiers has been averaged before 
applying the ANOVA. The statistical significance of the contribution of each component 
and interaction is denoted by red asterisks, with ‘***’ indicates p-values are smaller than 
0.001, ‘**’ indicates p-values are smaller than 0.01, and ‘*’ indicates p-values are smaller 
than 0.05. Among all components and interactions, the normalization contributes the 
most to the overall variance. Around a quarter of the overall variance belongs to residuals 
that cannot be explained by the factors considered. 
a Prediction 
Performance 
of NB OS (AUC) 
b Prediction 
 Performance 







Figure 45:  ANOVA for Prediction Performance of LUAD Survival. Analysis of 
variance (ANOVA) decomposes the overall variance in prediction performance of LUAD 
survival into various factors considered, including RNA-seq pipeline components and 
associated two-way interactions. Panels (a) and (b) show the ANOVA for prediction 
AUC and MCC, respectively. Prediction performance of various classifiers has been 
averaged before applying the ANOVA. The statistical significance of the contribution of 
each component and interaction is denoted by red asterisks, with ‘***’ indicates p-values 
are smaller than 0.001, ‘**’ indicates p-values are smaller than 0.01, and ‘*’ indicates p-
values are smaller than 0.05. Among all components and interactions, the mapping 
algorithm contributes the most to the overall variance. Note that more than a quarter of 





Performance of  
LUAD Survival (AUC) 
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3.3.2.5   Summary of Case Study 
We applied the 278 representative RNA-seq pipelines we investigated in Chapter 
2, Case Study 4 to the SEQC-neuroblastoma and TCGA-lung-adenocarcinoma datasets 
and examined whether the choice of various RNA-seq pipeline components would lead to 
variations in prediction performance of disease outcome. Our results showed that RNA-
seq pipeline components jointly affected prediction performance of disease outcome. 
These joint effects had not previously been reported in any studies. Unlike results 
presented in Chapter 2, Case Study 4, no single RNA-seq pipeline factors contributed 
dominantly to the overall variance of the prediction performance. However, many factors 
such as mapping algorithm, quantification, normalization, and some of their interactions 
had statistically significant contribution to the overall variance, and normalization usually 
contributed the most. 
3.4   Summary and Key Innovations 
In this chapter, I have addressed the second specific aim of this dissertation by 
designing experiments and implementing statistical modeling and machine learning 
techniques that facilitate robust knowledge discovery using features extracted from raw -
omic data. Knowledge discovery for -omic data can be categorized into two classes—
biomarker identification using statistical models and predictive modeling using 
supervised learning techniques. The chapter started with the introduction of popular 
statistical modeling and supervised learning frameworks specifically tailored to RNA-seq 
and ChIP-seq data. These methods were elaborated in the two case studies that focused 
on two major disease categories—cardiovascular diseases and cancers.  
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In the first case study, I studied various statistical modeling techniques for both 
RNA-seq and ChIP-seq datasets that facilitate biomarker identification (i.e., DEGs for the 
RNA-seq dataset and peaks for the ChIP-seq dataset). Though many methods were 
publicly available, only a few achieved both statistical and biological significance. Thus, 
through my studies, I established guidelines for robust DEG detection using RNA-seq 
and peak calling using ChIP-seq. In the second case study (i.e., the continuation of the 
SEQC project), we implemented a predictive modeling framework (i.e., the nested cross-
validation framework) that produced unbiased, robust prediction performance estimation 
for several disease endpoints we studied. We found that RNA-seq pipeline components 
jointly impacted the performance of predictive modeling. 
The key innovations of the work in this chapter are listed as follows: 
 I conducted the first DEG detection benchmarking study emphasizing both 
quantitative behavior and biological interpretation of DEGs. 
 I performed the largest RNA-seq pipeline investigation so far for two well-known 
biological datasets and identified key contributing factors for pipeline variability. 
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CHAPTER 4    
INTEGRATIVE ANALYSIS FOR PRECISION MEDICINE 
 
4.1   Introduction 
The scope of my dissertation centers on promoting precision medicine via 
addressing challenges in quality control (Chapter 2), knowledge discovery (Chapter 3), 
and integrative analysis (to be covered in Chapter 4). In Chapter 3, I introduced several 
techniques that facilitate knowledge discovery from good quality -omic features. -Omic 
data provide comprehensive annotations, maps, and catalogs that are beneficial for 
describing complicated dynamics in the human body. However, each type of -omic data 
captures only one aspect of molecular dynamics. To understand and model the entire 
dynamics, a combination of multi-omic data is necessary so as to provide adequate 
information for inferring and interpreting the true dynamics in cells. The concept of 
systems biology has been introduced and widely referred since 2000. The idea is to build 
the system-level understanding of the structure and dynamics in cells rather than inferring 
functions of a small part of the system using limited information [195]. In Chapter 4, I 
aim to address the third specific aim by integrating multiple sources of -omic data for 
improved disease subgroup assignment. 
There are many levels of integrative analysis. Following the DIKW hierarchy, the 
integration can be at the raw data level, information or feature level, knowledge level, or 
wisdom (i.e., actionable knowledge) level. This chapter focuses on knowledge-level 
integration aiming to improve the robustness of RNA-seq pipeline recommendation. The 
work in this chapter is in preparation for submission to Nature Methods. 
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4.2   Knowledge Integration Improving Pipeline Recommendation 
4.2.1   Background 
This case study is also part of the SEQC project, and it is the follow-up and 
integration of information described in both Case Study 4 in Chapter 2 (i.e., Section 
2.4.4) and Case Study 2 in Chapter 3 (i.e., Section 3.3.2). Please refer to Sections 2.4.4 
and 3.3.2 for detailed information about the RNA-seq pipeline study focusing on the 
benchmark datasets and the cancer datasets, respectively.  
The FDA first coordinated multiple sites of SEQC to generate the SEQC-
benchmark [148] and SEQC-neuroblastoma datasets [194], and then provided these 
datasets to SEQC teams to investigate the joint impact of pipeline components on 
downstream gene expression-based prediction in a two-phase study: 
In Phase-1, we developed benchmark metrics—accuracy, precision, reliability, 
and reproducibility—for assessing a representative set of 278 RNA-seq pipelines (Figure 
46, blue box) using the SEQC-benchmark dataset. 
In Phase-2, we validated the benchmark metrics by quantifying gene expression in 
the SEQC-neuroblastoma and TCGA-lung-adenocarcinoma datasets, and then 
determining if the benchmark metrics are informative for inferring downstream 
prediction of disease outcome (Figure 46, pink box). 
Our investigation revealed that RNA-seq pipeline components—mapping, 
quantification, and normalization—jointly impacted the accuracy, precision, reliability, 
and reproducibility of gene expression, and consequently, affected downstream 
performance of predicting disease outcome. RNA-seq pipelines that performed well in 






Figure 46:  The Workflow of the SEQC Project. The SEQC consortium developed and 
validated a guideline for selecting RNA-seq pipelines for gene expression-based 
predictive modeling using the SEQC-benchmark, SEQC-neuroblastoma, and TCGA-
lung-adenocarcinoma datasets. Phase-1 of the investigation involved development of 
metrics that captured the accuracy, precision, reliability, and reproducibility of RNA-seq 
pipelines (the blue box). Using the SEQC-neuroblastoma and TCGA-lung-
adenocarcinoma datasets, Phase-2 of the investigation determined that RNA-seq pipeline 
metrics can be used to select pipelines that result in better performance in terms of 





4.2.2   Experimental Design 
The objective of this case study is to show that integrating knowledge derived 
from various datasets (i.e., the SEQC-benchmark, SEQC-neuroblastoma, and TCGA-
lung-adenocarcinoma datasets) can improve the robustness of RNA-seq pipeline 
recommendations. As illustrated in Figure 47, for each dataset, we first ran the 278 or the 
156 RNA-seq pipelines, followed by calculating benchmark metrics for the SEQC-
benchmark dataset and estimating prediction performance for the SEQC-neuroblastoma 
and TCGA-lung-adenocarcinoma datasets. Knowledge derived from these datasets is the 
pipeline ranking based on each individual dataset. Pipeline ranking is dataset-dependent 
and information-depending (i.e., using benchmark metric performance or prediction 
performance as the reference). Thus, to provide a robust set of pipelines for RNA-seq 
expression analysis, it is necessary to integrate knowledge from multiple sources as 
indicated by the blue box in Figure 47. 
For the SEQC-benchmark dataset, there are eight benchmark metrics—accuracy, 
precision, reliability, and reproducibility for both all genes and low-expressing genes. 
The ranking of each benchmark metric can be encoded by either the percentage (0% 
represents the best-performing pipeline) or [1, 0, -1] (1:  pipeline ranking smaller than 
20%; -1:  pipeline ranking larger than 80%; 0:  otherwise). A pipeline belongs to the 
good-performing pipelines if either the median of the eight individual percentage ranking 
is less than 20%, or the sum of [1, 0, -1] ranking is greater than 4. In contrast, a pipeline 
belongs to the poor-performing pipelines if either the median of the eight individual 
percentage ranking is greater than 80%, or the sum of [1, 0, -1] ranking is less than -4. 
We use the same concept to determine the good-performing pipelines and poor-
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performing pipelines based on the prediction performance of the SEQC-neuroblastoma 
and TCGA-lung-adenocarcinoma datasets. The final set of good-performing and poor-
performing pipelines are based on the knowledge from all sources. 
 
 




Besides identifying a robust set of RNA-seq expression analysis pipelines, we 
also want to demonstrate that good- and poor-performing RNA-seq pipelines selected 
based on the benchmark metrics would lead to good and poor prediction performance of 
disease outcome, respectively (Figure 48). 
To achieve this objective, we first rank RNA-seq pipelines base on the median 
rank of the four benchmark metrics (i.e., accuracy, precision, reliability, and 
reproducibility). We then evaluate the utility of the benchmark metrics by examining 
whether good-performing and poor-performing pipelines identified based on the 
benchmark metrics were informative for inferring the performance of gene-expression-
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based prediction of disease outcome and statistical significance of patient stratification 
for all clinical endpoints (i.e., the SEQC-neuroblastoma EFS and OS endpoints and the 
TCGA-lung-adenocarcinoma survival endpoint).  
 
 




First, for the 278 representative RNA-seq pipelines applied to the SEQC-
benchmark dataset, we compute the median rank using a subset of the benchmark metrics 
as the final performance indicator for each pipeline. In total, we have 8 metrics (4 
benchmark metrics [accuracy, precision, reliability, reproducibility] × 2 gene sets [2,044 
low-expressing genes, 10,222 all genes]), and we investigate 45 subsets (3×15) of the 8 
metrics using the following criteria: 
(1) Fifteen combinations of the four benchmark metrics with at least one in a 
subset—one combination with all four benchmark metrics, four combinations 
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with three out of the four benchmark metrics, six combinations with two out 
of the four benchmark metrics, and four combinations with one metric. 
(2) Three subsets formed by metrics derived from all genes, those derived from 
low-expressing genes, or a combination of both. 
Second, for each of the 278 representative RNA-seq pipelines (156 for the 
TCGA-lung-adenocarcinoma survival endpoint), we calculate nested cross-validation 
AUC and MCC, resulting in 834 (468 for the TCGA-lung-adenocarcinoma survival 
endpoint) AUC and MCC values for each clinical endpoint (i.e., 278 pipelines × 3 
classifiers, or 156 pipelines × 3 classifiers). We also model survival functions based on 
the predicted labels of each sample using Kaplan-Meier analysis for each pipeline and 
each classifier.  We then use the two-tailed log-rank test to determine if estimated 
survival curves between the two predicted patient groups were statistically different. For 
each RNA-seq pipeline, we summarize the performance of gene-expression-based 
prediction of disease outcome using both the average AUC and MCC across classifiers 
and the success rate of patient stratification (i.e., statistically significant separation of two 
Kaplan-Meier curves) across all iterations and classifiers. 
Finally, we identified the top 20% good-performing pipelines and the bottom 20% 
poor-performing pipelines based on the median rank of a subset of the four benchmark 
metrics. The corresponding prediction performance (i.e., AUC and MCC) of the good-
performing pipelines was tested against that of the poor-performing pipelines using the 
one-sided Wilcoxon rank-sum test with the null hypothesis that the median of the former 
group was not larger than that of the latter group. 
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4.2.3   Results and Discussion 
For robust RNA-seq pipeline recommendation, the good-performing and poor-
performing RNA-seq pipelines are summarized in Figure 49. Key factors that 
contributed to good and poor performance were also listed. 
 
 




For knowledge validation, we ranked the 278 RNA-seq pipelines base on the 
median rank of a combination of the four benchmark metrics. We then investigated if 
good-performing and poor-performing pipelines identified based on the benchmark 
metrics were informative for inferring the performance of gene-expression-based 
prediction of disease outcome. 
For all endpoints, median prediction performance (i.e., AUC and MCC) of good-
performing pipelines was statistically significantly (p<0.05) larger than that of poor-
performing pipelines (Figure 50) based on the one-sided Wilcoxon rank-sum test. In 
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addition, good-performing pipelines (e.g., the [GSNAP un-spliced single-hit + Cufflinks 
+ median] pipeline) tended to result in higher success rates of patient stratification than 
poor-performing pipelines (e.g., the [BWA + RSEM + RLE] pipeline). Figure 51 
demonstrates Kaplan-Meier estimated survival functions for high-risk and low-risk 
patients for all endpoints. Good-performing pipelines tended to achieve statistically 
significant separation (p<0.05) of the two patient groups (Figure 51, panels a – c), while 
poor-performing pipelines were more likely to fail (Figure 51, panels d – f). 
In this case study, by integrating knowledge (i.e., good-performing and poor-
performing RNA-seq pipelines) from the three datasets, we were able to show that 
pipelines that performed well in the SEQC-benchmark dataset would also performed well 
in the SEQC-neuroblastoma and TCGA-lung-adenocarcinoma datasets. With the results 
demonstrated here, it becomes valid to recommend a robust set of RNA-seq pipelines that 














Figure 50:  Knowledge Validation for Pipeline Selection—Prediction Performance. 
RNA-seq pipelines selected based on benchmark metrics (i.e., accuracy, precision, 
reliability, and reproducibility) were informative for inferring the performance of gene-
expression-based prediction of disease outcome—(a) prediction performance measured 
by the area under the receiver operating characteristic curve (AUROC, or AUC) for the 
overall survival (OS) endpoint of the SEQC-neuroblastoma (NB) dataset; (b) prediction 
performance measured by the Matthews correlation coefficient (MCC) for the OS 
endpoint of the SEQC-NB dataset; (c) prediction performance measured by the AUC for 
the event-free survival (EFS) endpoint of the SEQC-NB dataset; (d) prediction 
performance measured by the MCC for the EFS endpoint of the SEQC-NB dataset; (e) 
prediction performance measured by the AUC for the survival endpoint of the TCGA-
lung-adenocarcinoma (LUAD) dataset; and (f) prediction performance measured by the 
MCC for the survival endpoint of the TCGA-LUAD dataset. The blue line in each panel 
shows the probability density of the prediction performance of good-performing RNA-
seq pipelines selected based on benchmark metrics; and the red line demonstrates that of 
poor-performing pipelines selected based on the same. Statistical significance (i.e., p-
values) was determined using the one-sided Wilcoxon rank-sum test. All panels show 
statistically significant difference between the two groups (i.e., prediction performance of 
good-performing pipelines vs. that of poor-performing pipelines). The good-performing 
and poor-performing pipelines were determined based on the average rank of each RNA-
seq pipeline over all benchmark metrics of low-expressing genes. 
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Figure 51:  Knowledge Validation for Pipeline Selection—Kaplan-Meier Analysis. 
The RNA-seq pipeline selection guide was validated by assessing the ability of pipelines 
to stratify patients based on Kaplan-Meier survival analysis. For each pipeline, patients 
were grouped by predictive labels (i.e., high risks vs. low risk), and two Kaplan-Meier 
curves were plotted. The two-tailed log-rank test was used to determine the statistical 
significance of the difference between the two curves. For good-performing pipelines 
selected based on benchmark metrics, the success rates of patient stratification (i.e., 
predictive labels led to statistically significant separation of Kaplan-Meier curves) were 
higher. For example, the success rates of the [GSNAP (un-spliced, single-hit) + Cufflinks 
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+ Median] pipeline were 93%, 70%, and 67% for the SEQC-NB OS, SEQC-NB-EFS, 
and TCGA-LUAD-Survival endpoints, respectively. Panels (a) to (c) demonstrate the 
most statistically significant separation of the two Kaplan-Meier curves for each 
endpoint. In contrast, poor-performing pipelines led to lower success rates of patient 
stratification. For instance, the success rates of the [BWA (un-spliced, single-hit) + 
RSEM + RLE] pipeline were 33%, 30%, and 33% for the SEQC-NB OS, SEQC-NB-
EFS, and TCGA-LUAD-Survival endpoints, respectively. Panels (d) to (f) demonstrate 




4.4   Summary and Key Innovations 
In this chapter, I have addressed the third specific aim of this dissertation by 
designing experiments that integrate knowledge from multiple datasets of the same type. 
The knowledge refers to pipeline rankings based on different datasets. Our integrative 
analysis provided a foundation for more robust, reliable RNA-seq pipeline 
recommendations. 
The key innovations of the work in this chapter are listed as follows: 
 I designed a knowledge integration workflow incorporating RNA-seq pipeline 
rankings based on different RNA-seq datasets that improves the robustness of 
RNA-seq pipeline recommendations. 
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CHAPTER 5    
CONCLUSION 
 
The concrete goals of this dissertation were to investigate and develop integrative 
bioinformatics approaches for extracting and discovering robust molecular knowledge for 
realizing future precision medicine. The specific technical achievements of this 
dissertation corresponding to the three research objectives are as follows: 
1. Investigated the impact of pipeline choice—component-wise and pipeline-wise—
on the quality of gene/transcript expression estimates for RNA-seq data; and 
established quality control guidelines for RNA-seq expression analysis pipelines 
2. Identified significant, predictive biomarkers for various clinical settings using 
statistical modeling and predictive modeling techniques; and established 
knowledge discovery guidelines for DEG detection 
3. Designed and implemented a workflow integrating pipeline rankings based on 
multiple RNA-seq datasets 
5.1   Concrete Innovation Deliverables 
The key innovations of this dissertation, as noted at the closing of each chapter, 
are summarized as follows: 
 (Chapter 2) I designed a comprehensive list of evaluation metrics that capture the 
performance of RNA-seq expression analysis pipeline. 
 (Chapter 2) I conducted the first investigation on genome annotation and 
proposed a novel, informative annotation complexity measure. 
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 (Chapter 2) I performed quantification pipeline investigation (among the first 
batch) and identified key factors for achieving accurate expression estimates. 
 (Chapter 2) I accomplished the simulation-based investigation on expression 
normalization (among the first batch). 
 (Chapter 2) I performed the largest investigation of RNA-seq expression analysis 
pipeline so far using well-designed benchmark datasets provided by FDA. 
 (Chapter 3) I conducted the first DEG detection benchmarking study emphasizing 
both quantitative behavior and biological interpretation of DEGs. 
 (Chapter 3) I performed the largest RNA-seq pipeline investigation so far for two 
well-known biological datasets and identified key contributing factors for pipeline 
variability. 
 (Chapter 4) I designed a knowledge integration workflow incorporating RNA-seq 
pipeline rankings based on different RNA-seq datasets that improves the 
robustness of RNA-seq pipeline recommendations. 
5.2   Directions for Future Research and Concluding Remarks 
5.2.1   -Omic Data Integration 
One notable effort that integrates multi-omic data for the improved understanding 
of cancer mechanisms is The Cancer Genome Atlas (TCGA) [196]. TCGA hosts public 
datasets of 27 cancer types with more than 11,000 patient cases. Each patient is annotated 
with clinical data (i.e. demographic, diagnostic, and survival data) and multimodal -omic 
data (i.e., genomic, transcriptomic, epigenomic, and proteomic).  
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We use head and neck squamous cell carcinoma (HNSCC) as an example to 
illustrate the integrative multi-omic study for precision medicine [197]. In 2014, a pan-
cancer study with twelve cancer types using multi-omic TCGA data was performed 
[198]. Among 3,527 samples in total, 305 were HNSCC. Six different data types (i.e. 
DNA copy number, methylation, mutation, and expression of mRNAs, miRNAs, and 
proteins) were analyzed both separately and integratively. By using clustering-based 
methods, pathway activities (inferred from gene expression and copy number data) have 
shown common copy number variations, mutation frequency patterns, and survival 
patterns between HNSCC and lung squamous cell carcinomas or some bladder cancers. 
Such integrative pan-cancer analysis provides more precise subtyping across multiple 
cancers sharing common molecular-level processes underlying cancer development. This 
new subtyping system reflects the essence of precision medicine.  
TCGA Research Network has published more than 30 articles describing multi-
omic investigation on numerous cancer types, and identified more precise, clinically 
relevant subtyping for multiple cancers [199-201] 
As illustrated by the TCGA case study, integrative multi-omic data analysis is of 
growing importance because it provides holistic view of molecular fingerprints for each 
patient’s condition. Recent research has shown positive impact of knowledge and insight 
obtained from integrative analysis of genomic and transcriptomic [202], transcriptomic 
and proteomic [203], and multiple -omic data types [111, 198] on disease diagnosis, 
prognosis, and treatment. The next important direction is the development of guidelines 
(or best practices) for -omic data integration and interpretation that will in turn enable 
better prediction of bio-system behavior, and safer and more effective therapeutics. 
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5.2.2   -Omic Data in EHR 
In a clinical setting, healthcare providers use electronic medical record (EMR) for 
clinical decision support. Thus, it is important to incorporate -omic data and knowledge 
into EMR. The Electronic Medical Records and Genomics (eMERGE) Network 
consortium aims to identify causal genomic variants (mostly SNPs) for EMR-based 
phenotypes and to integrate identified genotype-phenotype associations into the EMR 
system [204]. One crucial challenge is on how to store variants present in an individual or 
even in family members in the EMR [205]. The consortium has proposed several 
recommendations on augmenting the current EMR structure:  (1) it should store various 
genomic variants, such as SNPs, indels, and CNVs, in a discrete computable format; (2) it 
needs to satisfy interoperability to reduce the burden in data transfer and update within 
and between healthcare facilities; (3) it has to support rule-based decision support 
engines; and (4) it must contain abundant visualization elements for easier interpretation 
[206]. Another big challenge is that each individual typically has millions of variants. 
The consortium has proposed one potential solution that stores only known pathological 
variants in the EMR system. However, because the set of known pathological variants 
may change over time, this approach may lead to the inclusion of false positive and the 
exclusion of false negative variants. Thus, an alternative solution is to archive raw data in 
separate repositories easily accessible when necessary [207]. 
EMR is only for local clinic and hospital, while EHR contains and shares medical 
records among all participant clinics and hospitals [208]. Thus, interoperability is critical 
in using big data for precision medicine. Recently, the Health Level Seven International 
(HL7) proposed the Fast Healthcare Interoperability Resources (FHIR) standard that 
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addresses this important issue. On clinical genomics, several new FHIR resources and 
extension definitions are designed for variant data [209]. With such the standardized data 
exchange protocol, clinicians can utilize genomic information with other existing EHR 
data to determine the most effective treatment for each patient, which is a paradigm shift 
towards precision medicine. 
5.2.5   Concluding Remarks 
In this dissertation, I have addressed challenges in three fundamental building 
blocks, that is, quality control, knowledge discovery, and integrative analysis, for 
precision medicine, with the emphasis on analytics and models for NGS data. In the 
preceding sections, I have also discussed several potential directions building upon this 
work. Overall, this dissertation contributes to the research space by laying a foundation 
for future precision medicine. 
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APPENDIX B    
SUPPLEMENTARY NOTES FOR THE SEQC PROJECT 
 
Filtering the qPCR Benchmark Dataset to Produce a Reference Set of Genes 
Due to variability in qPCR measurements as well as disagreements among qPCR 
platforms [148], we filtered the qPCR dataset to retain only genes that exhibited 
“reliable” behavior. We then used these genes to evaluate the RNA-seq pipeline metrics. 
Filtering of the qPCR gene set is summarized in Figure 52. 
Starting with the initial set of 20,801 genes assayed with PrimePCR, we filtered 
these genes to retain only genes that were quantified as non-zero (i.e., detected) and with 
Ct (cycle threshold) values ≤ 35 (35 indicates detection of only a single molecule). 
Filtering PrimePCR data resulted in 14,014 genes that also matched with the AceView 
transcriptome used for mapping the SEQC-benchmark datasets with RNA-seq pipelines. 
Subsequently, we filtered the 14,014 qPCR genes to retain only those that 
exhibited the correct titration order (TO) and expected mixing ratio (EMR). Details of 
this process are in the following section titled “Filtering qPCR Genes by Titration Order 
and Expected Mixing Ratios.” 12,610 genes were retained after this process. 
Lastly, since some benchmark metrics such as accuracy and precision are 
sensitive to zero- or very low-expressing genes, we further selected genes that were 
expressed as non-zero in all replicates of all samples of all sequencing sites and all 278 
RNA-seq pipelines. The final reference set contains only 10,222 qPCR genes (referred to 




Figure 52:  Filtering Benchmark qPCR Genes. The 20,801 qPCR genes are first 
filtered to retain only 14,014 genes that are detectable and that match genes in the 
AceView transcriptome. Subsequently, genes are filtered to retain only the 12,610 genes 
that exhibit good titration order and expected mixing ratios. Finally, 10,222 genes 
(denoted as “All Genes”) that expressed in all replicates of all samples of all 278 RNA-
seq pipelines are retained for calculating evaluation metrics (i.e., accuracy, precision, 
reproducibility, and reliability). Among 10,222 genes, the 20% lowest-expressing genes 
(i.e., 2,044 genes; denoted as “Low-Expressing Genes”) are selected for calculating 




We also identified a set of low-expressing genes in the 10,222 genes based on the 
average qPCR expression of samples A, B, C, and D. The lowest 20% of the 10,222 
genes (i.e., 2,044 genes, referred to as “low-expressing genes”) were also used to 
compute the same set of benchmark metrics for RNA-seq pipelines. This design enabled 





Filtering qPCR Genes by Titration Order and Expected Mixing Ratios 
The SEQC-benchmark datasets (RNA-seq and qPCR) have unique properties that 
enable assessment of quantification reliability. After identifying detectable and AceView-
matched qPCR genes, we used two metrics (TO and EMR) to further filter the qPCR 
data, leaving only “reliable” qPCR genes. The TO and EMR metrics capture unique 
mixing properties of the data, that is,  












𝐵 . (22) 
Because of this property, all genes are expected to be expressed in one of the 
following orders, depending on the relative expression of samples A and B: 
𝐴 ≥ 𝐶 ≥ 𝐷 ≥ 𝐵   or   𝐴 ≤ 𝐶 ≤ 𝐷 ≤ 𝐵 . (23) 
The TO metric determines if genes are expressed in the correct order. The 
expression value of a qPCR gene is defined as 𝑦𝑠,𝑛,𝑘 where 𝑠 ∈ {𝐴, 𝐵, 𝐶, 𝐷} indicates the 
sample, 𝑛 = 1 … 𝑁 indicates the replicate, and 𝑘 = 1 … 𝐾 indicates the gene (for the 
PrimePCR set, N = 1; K = 10,222). For a qPCR dataset with multiple replicates, given 






𝑛=1  , 
(24) 
the set of all qPCR genes that follow the correct TO is 
𝐾𝑇𝑂 = {𝑘|(?̅?𝐴,∙,𝑘 ≥ ?̅?𝐶,∙,𝑘 ≥ ?̅?𝐷,∙,𝑘 ≥ ?̅?𝐵,∙,𝑘) ∨ ( ?̅?𝐴,∙,𝑘 ≤ ?̅?𝐶,∙,𝑘 ≤  ?̅?𝐷,∙,𝑘 ≤ ?̅?𝐵,∙,𝑘)} . (25) 
For a single replicate qPCR dataset (e.g., the PrimePCR dataset we analyzed), 
inherent variability of a single qPCR measurement may result in some false negative 
genes that follow the correct TO but fail to be identified. From the literature [210-213], 
the typical CoV for replicate qPCR measurements is around 15%, so we used this number 
to increase the margin for determining whether a gene follows the correct TO. 
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Mathematically, we calculated the width of one standard deviation of each qPCR 
measurement and used it as the margin. The revised equations for 𝐾𝑇𝑂 are as follow: 
𝑎 = 1.15, 𝑏 = 0.85, 
𝐾𝑇𝑂,𝐴≥𝐵 = {𝑘|(𝑎 ∙ ?̅?𝐴,𝑘 ≥ 𝑏 ∙ ?̅?𝐶,𝑘) ∧ (𝑎 ∙ ?̅?𝐶,𝑘 ≥ 𝑏 ∙ ?̅?𝐷,𝑘) ∧ (𝑎 ∙ ?̅?𝐷,𝑘 ≥ 𝑏 ∙ ?̅?𝐵,𝑘)} , 
𝐾𝑇𝑂,𝐴≤𝐵 = {𝑘|(𝑏 ∙ ?̅?𝐴,𝑘 ≤ 𝑎 ∙ ?̅?𝐶,𝑘) ∧ (𝑏 ∙ ?̅?𝐶,𝑘 ≤ 𝑎 ∙ ?̅?𝐷,𝑘) ∧ (𝑏 ∙ ?̅?𝐷,𝑘 ≤ 𝑎 ∙ ?̅?𝐵,𝑘)} , 
𝐾𝑇𝑂 = 𝐾𝑇𝑂,𝐴≥𝐵 ∪ 𝐾𝑇𝑂,𝐴≤𝐵 . 
(26) 
Besides the TO, samples should additionally exhibit a specific mixing ratio. 




 , (27) 







 , (28) 
where 𝑧 =
𝑚𝑅𝑁𝐴 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝐴
𝑚𝑅𝑁𝐴 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝐵
= 1.43, a correction factor for the difference in mRNA 
concentration between samples A and B [148].  




 of the same gene. As described earlier, the PrimePCR dataset contains only a 
single measurement for each sample, and thus, wider margins are needed for EMR metric 
calculation. Using the same technique, we calculated the width of one standard deviation 
of each ratio 
𝑅𝐴,𝐵 ∈ [𝑏 ∙ 𝑅𝐴,𝐵, 𝑎 ∙ 𝑅𝐴,𝐵] ≡ [𝑅𝐴,𝐵
𝐿𝑜𝑤𝑒𝑟 ,  𝑅𝐴,𝐵
𝑈𝑝𝑝𝑒𝑟 ] , 
𝑅𝐶,𝐷 ∈ [𝑏 ∙ 𝑅𝐶,𝐷 , 𝑎 ∙ 𝑅𝐶,𝐷] ≡ [𝑅𝐶,𝐷
𝐿𝑜𝑤𝑒𝑟 ,  𝑅𝐶,𝐷
𝑈𝑝𝑝𝑒𝑟 ] , 
(29) 
𝐸𝑀𝑅𝐶,𝐷 ∈ [𝑏 ∙ 𝐸𝑀𝑅𝐶,𝐷 , 𝑎 ∙ 𝐸𝑀𝑅𝐶,𝐷] ≡ [𝐸𝑀𝑅𝐶,𝐷
𝐿𝑜𝑤𝑒𝑟,  𝐸𝑀𝑅𝐶,𝐷
𝑈𝑝𝑝𝑒𝑟 ]) , 
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𝐿𝑜𝑤𝑒𝑟|𝑘,𝑅𝐶,𝐷≤𝐸𝑀𝑅𝐶,𝐷)} . (30) 
Regression Analysis 
We investigated the relationship between alignment profiles or gene expression 
distribution characteristics and benchmark metrics. The alignment profiles included the 
total number of mapped fragments, the total number of reads spanning the intronic 
region, the total number of reads with insertions or deletions, the total number of 
perfectly matched reads, the total number of reads with at most one mismatch, and the 
number of mismatches per mapped read. Each alignment algorithm was represented by 
the average statistics over 2 sequencing sites, 4 samples, 4 replicate libraries, and 2 lanes. 
Using the “MASS” package in R, we adopted the M-estimation with Huber weighting 
approach to fit robust linear regression models between a dependent variable (benchmark 
metric performance) and an explanatory variable (an alignment profile). The M-
estimation with Huber weighting approach is a regression method that is robust in the 
presence of outliers. The gene expression distribution characteristics included the lower 
quartile, median, upper quartile, maximum, interquartile range, standard deviation, 
skewness, kurtosis, and entropy of a gene expression distribution. We used the same M-
estimation with Huber weighting approach to fit robust linear regression models, and then 
reported the residual standard error for each model. 
Analysis of Variance for the SEQC Project 
We used analysis of variance (ANOVA) to determine if each RNA-seq pipeline 
factor significantly contributes to the variance of each of the four benchmark metrics (i.e., 
accuracy, precision, reliability, and reproducibility) as well as to the variance of 
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prediction performance (i.e., AUC and MCC). For each of the four benchmark metrics, 
we used a linear model (R function “lm”) to fit the data from all 278 pipelines using the 
metric as the dependent variable and the RNA-seq pipeline factors as independent 
categorical variables. We considered the following factors as independent categorical 
variables—mapping algorithm, mapping strategy (i.e., spliced vs. un-spliced), mapping 
reporting (i.e., single-hit vs. multi-hit), quantification algorithm, and normalization 
algorithm. We included all factors and their two-way interactions in the linear model. For 
each of the prediction endpoints, we applied the same technique to fit the data from all 
278 pipelines using average AUC or MCC as the dependent variable and the same set of 
RNA-seq pipeline factors as independent categorical variables. We then conducted the 
ANOVA on the linear model (R function “anova”). ANOVA calculates a “sum of 
squares” (i.e., variance) attributed to each factor or interaction and uses an F-test to 
determine if the variance is statistically significant. We calculated the percent that each 
factor or interaction contributes to the total variance by calculating the ratio of “sum of 
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